Skip Navigation

Advertise|Press|Contact|FAQ|CWConnect

Bookmark/Print/Share

Home » Clinical Trials » Search Clinical Trials
Therapeutic Areas: Neurology | Musculoskeletal | Family Medicine

Multiple Sclerosis Clinical Trials


A listing of Multiple Sclerosis medical research trials actively recruiting patient volunteers. Click on the closest city to find more detailed information on a research study in your area.

Alabama

Birmingham : Alabama Neurology Associates

A Safety Study of Combination Treatment With Avonex and Zocor in Relapsing Remitting Multiple Sclerosis

Birmingham : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Birmingham : Research Site

Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients

Cullman : North Central Neurology Associates, PC

Evaluation of Safety, Tolerability, and PK of VX15/2503 In Patients With MS

Cullman : Novartis Investigative Site

MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone

View More »

Cullman : North Central Neurology Associates PC

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Cullman : Teva Investigational Site 10329

The Efficacy and Safety and Tolerability of Laquinimod in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)

Arizona

Phoenix : St. Joseph’s Hospital and Medical Center

A Cooperative Clinical Study of Abatacept in Multiple Sclerosis (ACCLAIM)

View More »

Gilbert : Synthon investigational site 111

Efficacy and Safety of GTR in Comparison to Copaxone®

Glendale : Research Site

Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients

Phoenix : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Phoenix : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Phoenix : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Phoenix : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Phoenix : XenoPort Clinical Site

Arbaclofen Placarbil for the Treatment of Spasticity in Subjects With Multiple Sclerosis (MS)

Phoenix : Novartis Investigative Site

MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone

Phoenix : St. Joseph's Hospital Medical Center

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Sun City : Novartis Investigative Site

MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone

Tempe : Research Site

Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients

Tucson : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Tucson : Northwest NeuroSpecialists, PLLC

A Cross-Sectional Study of MSDx Complex 1 as a Marker for Active Disease in Multiple Sclerosis

Tucson : Northwest NeuroSpecialists, PLLC

A Study of MSDx Complex 1 as a Marker for Therapy Response in Multiple Sclerosis

Tucson : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Tucson : XenoPort Clinical Site

Arbaclofen Placarbil for the Treatment of Spasticity in Subjects With Multiple Sclerosis (MS)

Tucson : Northwest NeuroSpecialists, LLC

Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis

California

Berkeley : Jordan Research and Education Institute

A Cooperative Clinical Study of Abatacept in Multiple Sclerosis (ACCLAIM)

Los Angeles : University of Southern California - Keck School of Medicine

A Cooperative Clinical Study of Abatacept in Multiple Sclerosis (ACCLAIM)

View More »

Aliso Viejo : Avanir Pharmaceuticals

PRISM Registry: Pseudobulbar Affect Registry Series

Berkeley : Research Site

Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients

Berkeley : Alta Bates Summit Medical Center

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Carmichael : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Downey : Synthon investigational site 139

Efficacy and Safety of GTR in Comparison to Copaxone®

Fresno :

Efficacy and Safety Study of RPC1063 in Relapsing Multiple Sclerosis Patients

Fresno : Victoria Walton, MD

Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies

Fullerton : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Fullerton : Fullerton Neurology and Headache Center

Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies

Garden Grove : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Irvine : Synthon investigational site 112

Efficacy and Safety of GTR in Comparison to Copaxone®

La Jolla : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

La Jolla : Novartis Investigative Site

MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone

La Jolla : Research Site

Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients

Long Beach : Synthon investigational site 119

Efficacy and Safety of GTR in Comparison to Copaxone®

Long Beach : Research Site

Safety and Tolerability Study of MEDI-551, a B-cell Depleting Agent, to Treat Relapsing-Remitting Multiple Sclerosis

Los Angeles : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Los Angeles : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Los Angeles : Keck School of Medicine of the University of Southern Calfornia

Exploratory Study to Assess Clinical Response to Gilenya® (Fingolimod) in Relapsing Remitting Hispanic Multiple Sclerosis Forms

Los Angeles : USC MS Comprehensive Care Center & Research Group

Glatiramer Acetate for Multiple Sclerosis With Autoimmune Comorbidities

Los Angeles : Research Site

Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients

Los Angeles : USC

Trial of Memantine for Cognitive Impairment in Multiple Sclerosis

Newport Beach : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Newport Beach : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Newport Beach : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Newport Beach : Research Site

Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients

Newport Beach : Multiple Sclerosis Center of California & Research

Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies

Oakland : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Oceanside : Novartis Investigative Site

MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone

Orange : University of California, Irvine

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Pasadena : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Sacramento : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Sacramento : Novartis Investigative Site

MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone

Sacramento : Research Site

Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients

Sacramento : Sutter Institute for Medical Research

Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies

San Diego : XenoPort Clinical Site

Arbaclofen Placarbil for the Treatment of Spasticity in Subjects With Multiple Sclerosis (MS)

San Diego : Coordinated Clinical Research

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

San Francisco : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

San Francisco : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

San Francisco : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

San Francisco : University of California, San Francisco

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

San Francisco : University of California San Francisco

Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies

Stanford : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Temecula : Viking Clinical Research Center

Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies

Torrance : Research Site

Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients

Valencia : Sanguine Biosciences

A Biospecimen and Clinical Data Study on Patients With Alzheimer's, Multiple Sclerosis, Parkinson's, and Huntington's, for Drug & Biomarker Discovery

Colorado

Boulder : Alpine Clinical Research Center

New Investigational Medication for Relapsing Remitting Multiple Sclerosis (RRMS)

Boulder : Alpine Clinical Research Center

New Investigational Medication for Relapsing Remitting Multiple Sclerosis (RRMS) who have had a documented relapse in the last year

Centennial : 1st International Clinical Research Center

Do you have Relapsing Remitting Multiple Sclerosis?

View More »

Aurora : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Aurora : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Aurora : Research Site

Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients

Aurora : University of Colorado

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Boulder : Novartis Investigative Site

Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND)

Boulder : Novartis Investigative Site

MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone

Denver : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Denver : XenoPort Clinical Site

Arbaclofen Placarbil for the Treatment of Spasticity in Subjects With Multiple Sclerosis (MS)

Denver : Novartis Investigative Site

MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone

Denver : Research Site

Safety and Tolerability Study of MEDI-551, a B-cell Depleting Agent, to Treat Relapsing-Remitting Multiple Sclerosis

Englewood : Colorado Neurological Institute

Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies

Fort Collins : Novartis Investigative Site

MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone

Ft. Collins : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Ft. Collins : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Ft. Collins : Research Site

Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients

Connecticut

New London : Coastal Connecticut Research, LLC

Are You Currently Being Treated for a Relapsing Form of Multiple Sclerosis?

Pawcatuck : CNS Research of CT, Inc.

A 12-month, randomized, rater- and dose-blinded study to compare the efficacy and safety of fingolimod 0.25 mg and 0.5 mg administered orally once daily with glatiramer acetate 20 mg administered subcutaneously once daily in patients with relapsing-remitting multiple sclerosis.

View More »

Derby : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Derby : Novartis Investigative Site

MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone

Fairfield : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Fairfield : Synthon investigational site 134

Efficacy and Safety of GTR in Comparison to Copaxone®

Hartford : The Mandell Center for Multiple Sclerosis Updated

Assessing Tolerability of Avonex Intramuscular Injections

New Haven : Institute for Neurodegenerative Disorders

Study to Evaluate the Feasibility of [18F]Florbetapir PET for Assessment in MS Patients

New London : Synthon investigational site 124

Efficacy and Safety of GTR in Comparison to Copaxone®

Delaware

Newark : Research Site

Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients

Newark : Christiana Care Health Services

Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies

District of Columbia

DC : Research Site

Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients

Washington : Georgetown University Hospital

Efficacy and Safety of Baclofen ER Capsules (GRS) in Subjects With Spasticity Due to Multiple Sclerosis

Washington : Research Site

Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients

Washington D.C. : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Florida

Atlantis : Novartis Investigative Site

Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.

Bradenton : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Bradenton : Osmotica Study Site Updated

Efficacy Study of Arbaclofen to Treat Spasticity in Multiple Sclerosis

Bradenton : Brandenton Neurology, Inc.

Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies

Gainesville : Research Site

Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients

View More »

Hollywood : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Hollywood : Novartis Investigative Site

MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone

Hollywood : Sunrise Clinical Research, Inc.

Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies

Jacksonville : University of Florida

Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies

Maitland : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Maitland : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Maitland : Synthon investigational site 114

Efficacy and Safety of GTR in Comparison to Copaxone®

Maitland : Neurology Associates, PA

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Maitland : Neurology Associates, PA

Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies

Melbourne : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Miami : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Miami : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Miami : Research Site

Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients

Naples : Collier Neurologic Specialists

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

New Port Richey : Novartis Investigative Site

MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone

North Palm Beach : Laszlo J. Mate, MD

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Orlando : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Ormond Beach : Osmotica Study Site Updated

Efficacy Study of Arbaclofen to Treat Spasticity in Multiple Sclerosis

Ormond Beach : Novartis Investigative Site

MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone

Ormond Beach : Neurology Associates of Ormond Beach

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Ormond Beach : Neurology Associates of Ormond Beach

Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies

Pompano Beach : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Pompano Beach : Novartis Investigative Site

MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone

Pompano Beach : Neurological Associates

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Pompano Beach : Neurological Associates

Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies

Port Charlotte : XenoPort Clinical Site

Arbaclofen Placarbil for the Treatment of Spasticity in Subjects With Multiple Sclerosis (MS)

Port Charlotte : Synthon investigational site 120

Efficacy and Safety of GTR in Comparison to Copaxone®

Port Orange : Progressive Medical Research

Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies

Sarasota : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Sarasota : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Sarasota : Novartis Investigative Site

MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone

Sarasota : Roskamp Institute

Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies

South Miami : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

St. Petersburg : XenoPort Clinical Site

Arbaclofen Placarbil for the Treatment of Spasticity in Subjects With Multiple Sclerosis (MS)

St. Petersburg : Suncoast Neuroscience Associates, Inc.

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

St. Petersburg : Suncoast Neuroscience Associates, Inc

Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies

Sunrise : Synthon investigational site 130

Efficacy and Safety of GTR in Comparison to Copaxone®

Tallahassee : Novartis Investigative Site

MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone

Tallahassee : AMO Corporation

Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies

Tampa : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Tampa : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Tampa : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Tampa : XenoPort Clinical Site

Arbaclofen Placarbil for the Treatment of Spasticity in Subjects With Multiple Sclerosis (MS)

Tampa : Synthon investigational site 115

Efficacy and Safety of GTR in Comparison to Copaxone®

Tampa : Osmotica Study Site Updated

Efficacy Study of Arbaclofen to Treat Spasticity in Multiple Sclerosis

Tampa : Novartis Investigative Site

MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone

Tampa : Novartis Investigative Site

OL, Single-arm Extension Study to the Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5 mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis

Tampa : University of South Florida

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Tampa : Axiom Clinical Research of Florida

Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis

Vero Beach : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Vero Beach : Geodyssey Research, LLC

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Vero Beach : MS Center of Vero Beach

Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies

Vero Beach : Vero Beach Neurology

Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis

West Palm Beach : Novartis Investigative Site

MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone

Weston : Cleveland Clinic Florida

Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies

Georgia

Atlanta : NeuroTrials Research

Living with Multiple Sclerosis? Enrolling for a 96-week, non-placebo, comparative trial.

Atlanta : Neurotrials Research, Inc.

Multiple Sclerosis

View More »

Atlanta : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Atlanta : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Atlanta : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Atlanta : Novartis Investigative Site

MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone

Atlanta : Research Site

Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients

Atlanta : Shepard Center

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Atlanta : Shepherd Center

Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis

Decatur : Neurostudies

Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies

Hawaii

Honolulu : Leo Maher, MD

Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies

Illinois

Elk Grove Village : Alexian Brothers Hospital Network

A 6 month, randomized, active comparator, open-label, multi-center study to evaluate patient outcomes, safety and tolerability of Fingolimod (FTY720) 0.5mg/day in patients with relapsing remitting MS who are candidates for MS therapy change from previous disease modifying therapy (EPOC).

Flossmoor : South Suburban Neurology

A Cooperative Clinical Study of Abatacept in Multiple Sclerosis (ACCLAIM)

View More »

Barrington : Research Site

Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients

Champaign : Research Site

Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients

Chicago : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Chicago : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Chicago : Rush-Presbyterian St. Luke's Medical Center

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Chicago : University of Chicago

Tysabri Effects on Cognition and Neurodegeneration in Multiple Sclerosis

Elk Grove Village : Synthon investigational site 107

Efficacy and Safety of GTR in Comparison to Copaxone®

Evanston : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Flossmoor : Novartis Investigative Site

MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone

Flossmoor : South Suburban Neurology

Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies

Lake Barrington : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Lake Barrington : XenoPort Clinical Site

Arbaclofen Placarbil for the Treatment of Spasticity in Subjects With Multiple Sclerosis (MS)

Lake Barrington : Research Site

Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients

Lille Cedex : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Northbrook : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Northbrook : Synthon investigational site 132

Efficacy and Safety of GTR in Comparison to Copaxone®

Northbrook : Consultants in Neurology

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Peoria : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Peoria : Research Site

Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients

Indiana

Avon : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Ft. Wayne : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Indianapolis : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Indianapolis : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Indianapolis : XenoPort Clinical Site

Arbaclofen Placarbil for the Treatment of Spasticity in Subjects With Multiple Sclerosis (MS)

View More »

Indianapolis : Novartis Investigative Site

MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone

Indianapolis : Research Site

Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients

Indianapolis : Josephson Wallack Munshower Neurology, P.C.

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Indianapolis : Josephson Wallack Munshower Neurology, PC

Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis

Merrillville : Neuroscience Institute

Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies

Wayne : Osmotica Study Site Updated

Efficacy Study of Arbaclofen to Treat Spasticity in Multiple Sclerosis

Iowa

Des Moines : Mercy Ruan Neurology Clinic Res Ct.

Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies

Kansas

Lenexa : MidAmerica Neuroscience Research Foundation DBA: Rowe Neurology Institute

A Cooperative Clinical Study of Abatacept in Multiple Sclerosis (ACCLAIM)

View More »

Kansas City : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Kansas City : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Kansas City : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Kansas City : Synthon investigational site 118

Efficacy and Safety of GTR in Comparison to Copaxone®

Kansas City : University of Kansas Medical Center

Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis

Lenexa : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Lenexa : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Lenexa : XenoPort Clinical Site

Arbaclofen Placarbil for the Treatment of Spasticity in Subjects With Multiple Sclerosis (MS)

Lenexa : Osmotica Study Site Updated

Efficacy Study of Arbaclofen to Treat Spasticity in Multiple Sclerosis

Lenexa : Novartis Investigative Site

MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone

Lenexa : MidAmerica Neuroscience Institute

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Lenexa : Mid America Neuroscience Institute

Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies

Overland Park : Research Site

Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients

Topeka : Precise Clinical Research

Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies

Topeka : Cotton O'Neil Clinical Research Institute

Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies

Kentucky

Lexington : Associates in Neurology, P.S.C.

A Phase 3 study of PEGylated Interferon Beta-1a vs Placebo for subjects with Relapsing Remitting Multiple Sclerosis.

Lexington : Associates in Neurology, P.S.C.

A Phase 3 Study to determine the Efficacy and Safety of Daclizumab High Yield Process (DAC HYP) versus Avonex (Interferon-beta-1a) in Patients with Relapsing-Remitting Multiple Sclerosis.

Lexington : Associates in Neurology, P.S.C.

A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study to evaluate the efficacy and safety of Ocrelizumab in comparison to Interferon Beta-1a (Rebif) in patients with Relapsing Multiple Sclerosis.

Lexington : Associates in Neurology, P.S.C.

Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of Two Doses of Oral Dalfampridine Extended Release Tablets (5 mg and 10mg twice daily) in Patients with Multiple Sclerosis. Sponsored by: Acorda Therapeutics.

Lexington : University of Kentucky Chandler Medical Center

Help us to make progress in Secondary Progressive MS

Lexington : Associates in Neurology, P.S.C.

Multicenter, open-labeled, randomized, active comparator research study to evaluate patient outcome, safety and tolerability of an investigational medicine in patients with Relapsing forms of Multiple Sclerosis and who are candidates for MS therapy change from previous disease modifying therapy.

Lexington : Associates in Neurology, P.S.C.

This trial is evaluating the safety and efficacy of an investigational oral medication for the treatment of spasticity in patients with multiple sclerosis (MS).

View More »

Lexington : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Lexington : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Lexington : XenoPort Clinical Site

Arbaclofen Placarbil for the Treatment of Spasticity in Subjects With Multiple Sclerosis (MS)

Lexington : Research Site

Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients

Lexington : Associates in Neurology

Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies

Lexington : Associates in Neurology

Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis

Louisville : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Louisville : Synthon investigational site 140

Efficacy and Safety of GTR in Comparison to Copaxone®

Louisville : University of Louisville (recruiting nationwide)

Exploratory Study on the Timing of Multiple Sclerosis (MS) Symptoms

Louisville : Novartis Investigative Site

MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone

Louisville : Research Site

Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients

Louisville : Norton Healthcare, Inc.

Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies

Louisiana

Shreveport : Louisiana State University

A Cooperative Clinical Study of Abatacept in Multiple Sclerosis (ACCLAIM)

Maine

Scarbrough : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Maryland

Baltimore : University of Maryland

A Cooperative Clinical Study of Abatacept in Multiple Sclerosis (ACCLAIM)

View More »

Baltimore : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Baltimore : Research Site

Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients

Baltimore : Johns Hopkins University School of Medicine

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Baltimore : University of Maryland

Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies

Baltimore : Johns Hopkins University

Using Optical Coherence Tomography (OCT) to Evaluate the Efficacy and Safety of PEGylated Interferon Beta-1a (BIIB017) in Patients With Relapsing Multiple Sclerosis

Bethesda : Bethesda Neurology, LLC

Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies

Massachusetts

Bellingham : CNS Research of MA, Inc.

A 12-month, randomized, rater- and dose-blinded study to compare the efficacy and safety of fingolimod 0.25 mg and 0.5 mg administered orally once daily with glatiramer acetate 20 mg administered subcutaneously once daily in patients with relapsing-remitting multiple sclerosis.

Boston : Brigham Women’s Hospital

A Cooperative Clinical Study of Abatacept in Multiple Sclerosis (ACCLAIM)

Brockton : Beacon Clinical Research

Are You Currently Being Treated for a Relapsing Remitting Form of Multiple Sclerosis?

View More »

Boston : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Boston : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Boston : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Boston : Research Site

Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients

Boston : Beth Israel Deaconess Medical Center

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Boston : Caritas St. Elizabeth's Hospital

Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies

Brookline : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Burlington : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Cambridge : Novartis Investigative Site

Pregnancy Registry Trial

Cambridge : Outcome Sciences, Inc

Prospective Observational Long-term Safety Registry of Multiple Sclerosis Patients Who Have Participated in Cladribine Clinical Trials

Lexington : Research Site

Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients

Milford : Milford Regional Medical Center

Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies

Springfield : Novartis Investigative Site

MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone

Springfield : Springfield Neurology Associates, LLC

Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies

Worcester : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Worcester : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Worcester : Research Site

Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients

Worcester : Fallon Clinic at Worcester Medical Center

Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies

Michigan

Ann Arbor : Michigan Head-Pain & Neurological Institute Updated

Clinical Trial for the treatment of spasticity in Patients with MS

Ann Arbor : Michigan Head-Pain & Neurological Institute Updated

Clinical Trial for the treatment of spasticity in Patients with MS

Bingham Farms : QUEST Research Institute

Multiple Sclerosis Spasticity Study

View More »

Ann Arbor : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Ann Arbor : Osmotica Study Site Updated

Efficacy Study of Arbaclofen to Treat Spasticity in Multiple Sclerosis

Bingham Farms : XenoPort Clinical Site

Arbaclofen Placarbil for the Treatment of Spasticity in Subjects With Multiple Sclerosis (MS)

Clinton TWP : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Clinton Twp : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Clinton Twp : Michigan Neurology Associates, P.C.

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Detroit : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Detroit : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Detroit : Novartis Investigative Site

MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone

Detroit : Henry Ford Health System

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Detroit : Wayne State University

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

East Lansing : Research Site

Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients

Farmington Hills : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Farmington Hills : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Minneapolis : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Novi : Novartis Investigative Site

MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone

Minnesota

Minneapolis : University of Minnesota

A Cooperative Clinical Study of Abatacept in Multiple Sclerosis (ACCLAIM)

View More »

Edina : Minneapolis Clinic of Neurology

Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies

Golden Valley : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Golden Valley : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Golden Valley : Synthon investigational site 103

Efficacy and Safety of GTR in Comparison to Copaxone®

Mississippi

Jackson : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Missouri

Chesterfield : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Kansas City : Saint Luke's Hospital

Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies

Springfield : St.John's Research Institute, Inc

Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies

St. Louis : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

St. Louis : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

View More »

St. Louis : Washington University (John L. Trotter MS Center)

Ampyra for Optic Neuritis in MS

St. Louis : Novartis Investigative Site

MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone

Montana

Great Falls : Novartis Investigative Site

MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone

Great Falls : Advanced Neurology Specialists

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Great Falls : Benefis Physician Associates

Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies

Nebraska

Lincoln : Research Site

Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients

Lincoln : Neurology Associates PC

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Omaha : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Omaha : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

New Hampshire

Lebanon : Dartmouth Hitchcock Medical Center

A Cooperative Clinical Study of Abatacept in Multiple Sclerosis (ACCLAIM)

View More »

Lebanon : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

New Jersey

Freehold : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Marlton : Research Site

Safety and Tolerability Study of MEDI-551, a B-cell Depleting Agent, to Treat Relapsing-Remitting Multiple Sclerosis

Newark : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Newark : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Newark : UMDNJ

Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies

View More »

Teaneck : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Teaneck : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Teaneck : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Toms River : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Toms River : XenoPort Clinical Site

Arbaclofen Placarbil for the Treatment of Spasticity in Subjects With Multiple Sclerosis (MS)

New Mexico

Albuquerque : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Albuquerque : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

New York

Buffalo : Jacobs Neurological Institute Buffalo General Hospital

A Cooperative Clinical Study of Abatacept in Multiple Sclerosis (ACCLAIM)

Mineola : Winthrop University Hospital Clinical Trials Center

Multiple Sclerosis - (MS) Primary Progressive Multiple Sclerosis

New York : Judith Jaffe Multiple Sclerosis Center

A Cooperative Clinical Study of Abatacept in Multiple Sclerosis (ACCLAIM)

View More »

Albany : Novartis Investigative Site

MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone

Albany : Albany Medical Center Hospital

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Albany : Neurological Associates of Albany, PC

Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies

Amherst : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Latham : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Latham : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Latham : Empire Neurology, PC

Evaluation of Safety, Tolerability, and PK of VX15/2503 In Patients With MS

Latham : Research Site

Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients

Latham : Empire Neurology, PC

Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies

New York : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

New York : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

New York : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

New York : Research Site

Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients

New York : NYU-Hospital for Joint Diseases

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

New York : Mount Sinai School of Medicine

Study to Evaluate Intravenous and Oral Steroids for Multiple Sclerosis Attacks

Patchogue : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Patchogue : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Patchogue : XenoPort Clinical Site

Arbaclofen Placarbil for the Treatment of Spasticity in Subjects With Multiple Sclerosis (MS)

Patchogue : Novartis Investigative Site

MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone

Patchogue : Research Site

Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients

Patchogue : South Shore Neurologic Associates

Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies

Plainview : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Plainview : XenoPort Clinical Site

Arbaclofen Placarbil for the Treatment of Spasticity in Subjects With Multiple Sclerosis (MS)

Plainview : Novartis Investigative Site

MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone

Plainview : Research Site

Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients

Plainview : Island Neurological Associates

Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies

Plainview : Island Neurological Assoicates, PC

Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis

Rochester : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Rochester : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Rochester : University of Rochester

Lubiprostone in Patients With Multiple Sclerosis Associated Constipation

Rochester : University of Rochester

Memantine for Spasticity in MS Patients

Rochester : University of Rochester

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Rochester : University of Rochester Medical Center

Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies

Stony Brook : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Stony Brook : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Stony Brook : Stony Brook University

Mindfulness Based Stress Reduction in Multiple Sclerosis (MS)

Stony Brook : SUNY at Stony Brook

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

White Plains : Research Site

Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients

North Carolina

Chapel Hill : University of North Carolina

A Cooperative Clinical Study of Abatacept in Multiple Sclerosis (ACCLAIM)

Charlotte : PMG Research of Charlotte

Multiple Sclerosis (MS) Research Opportunity

Charlotte : Duke University

The MURDOCK Study Community Registry and Biorepository Multiple Sclerosis Cohort

Concord : Duke University

The MURDOCK Study Community Registry and Biorepository Multiple Sclerosis Cohort

Winston Salem : PMG Research of Winston-Salem

Have you been diagnosed with a relapsing form of Multiple Sclerosis?

View More »

Advance : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Advance : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Advance : Research Site

Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients

Asheville : XenoPort Clinical Site

Arbaclofen Placarbil for the Treatment of Spasticity in Subjects With Multiple Sclerosis (MS)

Asheville : Novartis Investigative Site

Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.

Chapel Hill : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Charlotte : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Charlotte : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Charlotte : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Charlotte : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Charlotte : Synthon investigational site 125

Efficacy and Safety of GTR in Comparison to Copaxone®

Charlotte :

Efficacy and Safety Study of RPC1063 in Relapsing Multiple Sclerosis Patients

Charlotte : Osmotica Study Site Updated

Efficacy Study of Arbaclofen to Treat Spasticity in Multiple Sclerosis

Charlotte : The Neurological Institute, PA

Evaluation of Safety, Tolerability, and PK of VX15/2503 In Patients With MS

Charlotte : Novartis Investigative Site

MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone

Charlotte : Carolinas Medical Center

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Charlotte : The Neurological Institute, PA

Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies

Hickory : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

High Point : Cornerstone Neurology

NAPS-MS: NAtalizumab Effects on Parameters of Sleep in Patients With Multiple Sclerosis Experiencing Fatigue or Sleepiness

Raleigh : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Raleigh : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Raleigh : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Raleigh : Synthon investigational site 141

Efficacy and Safety of GTR in Comparison to Copaxone®

Raliegh :

Efficacy and Safety Study of RPC1063 in Relapsing Multiple Sclerosis Patients

Winston-Salem : Research Site

Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients

Winston-Salem : Research Site

Safety and Tolerability Study of MEDI-551, a B-cell Depleting Agent, to Treat Relapsing-Remitting Multiple Sclerosis

North Dakota

Bismarck : Legacy Pharma Research

MS - Central Neuropathic Pain due to Multiple Sclerosis

Bismarck : Legacy Pharma Research

MS - Central Neuropathic Pain due to Multiple Sclerosis

View More »

Grand Forks : Research Site

Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients

Ohio

Akron : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Akron : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Akron : XenoPort Clinical Site

Arbaclofen Placarbil for the Treatment of Spasticity in Subjects With Multiple Sclerosis (MS)

Akron :

Efficacy and Safety Study of RPC1063 in Relapsing Multiple Sclerosis Patients

Akron : Novartis Investigative Site

MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone

View More »

Bellevue : Novartis Investigative Site

MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone

Cincinnati : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Cleveland : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Cleveland : Synthon investigational site 106

Efficacy and Safety of GTR in Comparison to Copaxone®

Cleveland : Research Site

Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients

Cleveland : Cleveland Clinic Foundation

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Columbus : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Columbus : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Columbus : Novartis Investigative Site

MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone

Columbus : Teva Investigational Site 10317

The Efficacy and Safety and Tolerability of Laquinimod in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)

Dayton : Synthon investigational site 135

Efficacy and Safety of GTR in Comparison to Copaxone®

Dayton : Novartis Investigative Site

MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone

Dayton : Research Site

Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients

Dayton : Neurology Specialists, Inc.

Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies

Dayton : Neurology Specialists, Inc

Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis

Gahanna : Research Site

Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients

Uniontown : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Uniontown : Research Site

Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients

Oklahoma

Oklahoma City : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Oklahoma City : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Oklahoma City : Novartis Investigative Site

MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone

Oklahoma City : Oklahoma Medical Research Foundation

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Oregon

Eugene : Clinical Trials of America, Inc

Male and female aged 18-65 years, have you been diagnosed with multiple sclerosis?

Portland : Providence St. Vincent Medical Center

A Cooperative Clinical Study of Abatacept in Multiple Sclerosis (ACCLAIM)

View More »

Clackamas : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Corvallis : The Corvallis Clinic, P.C.

Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies

Medford : Providence Medical Group - Medford

Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis

Portland : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Portland : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Portland : Oregon Health and Science University

Dalfampridine for Imbalance in Multiple Sclerosis

Portland : Research Site

Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients

Portland : Providence Multiple Sclerosis Center

Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies

Portland : Providence St. Vincent Medical Center - Northwest MS Center

Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis

Pennsylvania

Abington : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Abington : Synthon investigational site 132

Efficacy and Safety of GTR in Comparison to Copaxone®

Abington : Research Site

Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients

Allentown : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Altoona : Novartis Investigative Site

MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone

View More »

Greensburg : Westmoreland Neurology

Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies

Indiana : Synthon investigational site 109

Efficacy and Safety of GTR in Comparison to Copaxone®

Philadelphia : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Philadelphia : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Philadelphia : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Philadelphia : Drexel University College of Medicine

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Philadelphia : University of Pennsylvania Health System

Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies

Pittsburgh : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Pittsburgh : Osmotica Study Site Updated

Efficacy Study of Arbaclofen to Treat Spasticity in Multiple Sclerosis

Pittsburgh : Research Protocol Management Solutions

Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies

Wilkes Barre : Geisinger Health System

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Rhode Island

Providence : CNS Research of RI, Inc.

A 12-month, randomized, rater- and dose-blinded study to compare the efficacy and safety of fingolimod 0.25 mg and 0.5 mg administered orally once daily with glatiramer acetate 20 mg administered subcutaneously once daily in patients with relapsing-remitting multiple sclerosis.

Providence : The Neurology Foundation, Inc.

A Cooperative Clinical Study of Abatacept in Multiple Sclerosis (ACCLAIM)

View More »

Providence : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

South Carolina

Greenville : Duke University

The MURDOCK Study Community Registry and Biorepository Multiple Sclerosis Cohort

View More »

Greenville : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Tennessee

Franklin : Advanced Neurosciences Institute

A Cooperative Clinical Study of Abatacept in Multiple Sclerosis (ACCLAIM)

View More »

Cordova : Research Site

Safety and Tolerability Study of MEDI-551, a B-cell Depleting Agent, to Treat Relapsing-Remitting Multiple Sclerosis

Franklin : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Franklin : XenoPort Clinical Site

Arbaclofen Placarbil for the Treatment of Spasticity in Subjects With Multiple Sclerosis (MS)

Franklin : Synthon investigational site 137

Efficacy and Safety of GTR in Comparison to Copaxone®

Franklin : Advanced Neurosciences Institute

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Knoxville : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Knoxville : Novartis Investigative Site

MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone

Memphis : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Nashville : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Nashville : XenoPort Clinical Site

Arbaclofen Placarbil for the Treatment of Spasticity in Subjects With Multiple Sclerosis (MS)

Nashville : Novartis Investigative Site

MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone

Texas

Amarillo : Texas Oncology

High Dose Chemo With Stem Cell Transplant as Treatment for Multiple Sclerosis That Failed Prior Treatment

Dallas : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Dallas : Novartis Investigative Site

MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone

Dallas : Baylor Research Institute

Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies

Dallas : University of Texas Southwestern

Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies

View More »

Dallas : UT Southwestern

Trial of Memantine for Cognitive Impairment in Multiple Sclerosis

Houston : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Houston : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Houston : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Houston : Baylor College of Medicine

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Houston : Research Site

Safety and Tolerability Study of MEDI-551, a B-cell Depleting Agent, to Treat Relapsing-Remitting Multiple Sclerosis

Lubbock : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Round Rock : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Round Rock : Novartis Investigative Site

MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone

Round Rock : Research Site

Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients

Round Rock : Central Texas Neurology Consultants, P.A.

Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies

Round Rock : Central Texas Neurology

Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis

San Antonio : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

San Antonio : Osmotica Study Site Updated

Efficacy Study of Arbaclofen to Treat Spasticity in Multiple Sclerosis

San Antonio : Novartis Investigative Site

MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone

San Antonio : Innovative Clinical Trials, Bexar Diagnostic Medicine Assoc.

Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies

San Antonio : Integra Clinical Research, LLC

Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis

Sherman : Texoma Neurology Associates

Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies

Terrell : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Utah

Salt Lake City : Rocky Mountain MS Clinic

A Pilot Study to Assess microRNA Biomarkers in Early and Later Stage Multiple Sclerosis

Salt Lake City : Rocky Mountain MS Clinic

Analysis of Lymphocyte Cell Surface Adhesion Marker Expression in Natalizumab Population With Active Control

Salt Lake City : Novartis Investigative Site

MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone

Salt Lake City : Research Site

Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients

Salt Lake City : Rocky Mountain MS Clinic

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Vermont

Burlington : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Burlington : Fletcher Allen Health Care - Neurology Service

Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis

Virginia

Charlottesville : Charlottesville Medical Research

Are You Currently Being Treated for a Relapsing Remitting Form of Multiple Sclerosis?

Charlottesville : Charlottesville Medical Research

Suffering from Relapsing Remitting Form of Multiple Sclerosis?

View More »

Charlottesville : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Charlottesville : Synthon investigational site 122

Efficacy and Safety of GTR in Comparison to Copaxone®

Henrico : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Henrico : Novartis Investigative Site

MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone

Henrico : Neurological Associates

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Newport News : Research Site

Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients

Newport News : Hampton Roads Neurology

Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis

Norfolk : Research Site

Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients

Roanoke : Novartis Investigative Site

MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone

Vienna : XenoPort Clinical Site

Arbaclofen Placarbil for the Treatment of Spasticity in Subjects With Multiple Sclerosis (MS)

Vienna : MS Center of Greater Washington

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Washington

Lynnwood : Clinical Trials of America, Inc

Are you a man or woman over 18, and suffering from spasticity due to multiple sclerosis?

Seattle : Benaroya Research Institute at Virginia Mason

A Cooperative Clinical Study of Abatacept in Multiple Sclerosis (ACCLAIM)

View More »

Issaquah : Swedish Neuroscience Institute

Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis

Kirkland : MS Center at Evergreen

A Placebo Controlled Trial of Dalfampridine ER for Ambulatory Activity in People With Multiple Sclerosis

Kirkland : MS Center at Evergreen Healthcare

Diclofenac Sodium Topical Gel to Reduce Injection Site Discomfort in Patients With Multiple Sclerosis Taking Glatiramer Acetate

Kirkland : MS Center at Evergreen Hospital

Validation of Hand Held Dynamometer for Assessment of Lower Limb Muscle Strength in Multiple Sclerosis

Mountlake Terrace :

Safety and Efficacy Study OnabotulinumtoxinA for the Treatment of Urinary Incontinence in Multiple Sclerosis

Seattle : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Seattle : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Seattle : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Seattle :

Efficacy and Safety Study of RPC1063 in Relapsing Multiple Sclerosis Patients

Seattle : Novartis Investigative Site

MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone

Seattle : Research Site

Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients

Seattle : Swedish Medical Center

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Seattle : Research Site

Safety and Tolerability Study of MEDI-551, a B-cell Depleting Agent, to Treat Relapsing-Remitting Multiple Sclerosis

Seattle : Swedish Neuroscience Institute

Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies

Seattle : Pacific Medical Centers

Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies

Seattle : Swedish Neuroscience Institute

Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis

Seattle : MS Hub

Trial of Memantine for Cognitive Impairment in Multiple Sclerosis

Tacoma : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Tacoma : XenoPort Clinical Site

Arbaclofen Placarbil for the Treatment of Spasticity in Subjects With Multiple Sclerosis (MS)

Tacoma : Research Site

Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients

Tacoma : MultiCare Health System

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Tacoma : MultiCare Research Institute

Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies

West Virginia

Morgantown : United BioSource Corporation

Pregnancy Exposure Registry for Tysabri

Wisconsin

Green Bay : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Milwaukee : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Albania

Many Locations :

Noninterventional Study Assessing Cognitive Function and Physical Activity in People With Multiple Sclerosis

Argentina

Buenos Aires : Fundación Argentina Contra las Enfermedades Neurológicas del Envejecimiento - FACENE

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Buenos Aires : Hospital Churruca-Visca

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Capital Federal : Novartis Investigative Site

Safety and Tolerability of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis

Ciudad Autonoma Bs As : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Ciudad Autonoma de Buenos Aires : Instituto de Neurologia Cognitiva

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

View More »

Ciudad Autonoma de Buenos Aires : Hospital Britanico de Buenos Aires

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Ciudad Autonoma de Buenos Aires : Medeos - Centro de Medicina Integral e Investigación Clínica

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Ciudad Autónoma de Buenos Aires : Hospital Italiano

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Ciudad de Buenos Aires : Instituto Argentino de Investigacion Neurologica

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Ciudad de Buenos Airesa : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Guaymallen : Novartis Investigative Site

Safety and Tolerability of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis

Many Locations :

Noninterventional Study Assessing Cognitive Function and Physical Activity in People With Multiple Sclerosis

Rosario : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Salta : Novartis Investigative Site

Safety and Tolerability of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis

San Juan : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

San Miguel de Tucumán : Novartis Investigative Site

Safety and Tolerability of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis

Australia

Fitzroy : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Hobart : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Kanwal : Novartis Investigative Site

Efficacy of Fingolimod in de Novo Patients Versus Fingolimod in Patients Previously Treated With a First Line Disease Modifying Therapy

Austria

Innsbruck : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Linz : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Linz : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Linz : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

Many Locations :

Study Evaluating Betaferons® Safety and Tolerability In Pediatric Patients With Multiple Sclerosis

View More »

Salzburg : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Vienna : Novartis Investigative Site

Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND)

Vienna : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

Wien : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Belarus

Bitebsk : Synthon investigational site 401

Efficacy and Safety of GTR in Comparison to Copaxone®

Gomel : Synthon investigational site 402

Efficacy and Safety of GTR in Comparison to Copaxone®

Grodno : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Grodno : Synthon investigational site 403

Efficacy and Safety of GTR in Comparison to Copaxone®

Minsk : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

View More »

Minsk : Synthon investigational site 404

Efficacy and Safety of GTR in Comparison to Copaxone®

Minsk : Synthon investigational site 407

Efficacy and Safety of GTR in Comparison to Copaxone®

Minsk : Synthon investigational site 408

Efficacy and Safety of GTR in Comparison to Copaxone®

Minsk : XX

Phase 3 Study to Evaluate Efficacy and Safety of NU100 in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)

Vitebsk : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Vitebsk : Synthon investigational site 405

Efficacy and Safety of GTR in Comparison to Copaxone®

Belgium

Antwerpen : Research Site

Avonex-evaluation of Quality of Life and Convenience in Belgian Patients - The AVAIL Study

Ath : Research Site

Exploratory Study to Assess the Effect of Fampridine on Walking Ability and Balance in Patients With Multiple Sclerosis.

Brabant Wallon : Research Site

Avonex-evaluation of Quality of Life and Convenience in Belgian Patients - The AVAIL Study

Brasschaat : Research Site

Exploratory Study of the Safety, Tolerability and Efficacy of Multiple Regimens of Natalizumab in Adult Subjects With Relapsing MS

Brugge : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

View More »

Brussels : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Bruxelles : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Bruxelles : Research Site

Avonex-evaluation of Quality of Life and Convenience in Belgian Patients - The AVAIL Study

Charleroi : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Edegem : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Esneux : Centre Hospitalier Universitaire de Liège Ourthe Ambléve

Efficacy of Clean Intermittent Catheterization in MS Patients With Bladder Dysfunction

Hainaut : Research Site

Avonex-evaluation of Quality of Life and Convenience in Belgian Patients - The AVAIL Study

Kortrijk : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

La Louviere : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

La Louviere : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Leuven : UZ Gasthuisberg

Efficacy of Clean Intermittent Catheterization in MS Patients With Bladder Dysfunction

Leuven : Research Site

Exploratory Study to Assess the Effect of Fampridine on Walking Ability and Balance in Patients With Multiple Sclerosis.

Liege : Research Site

Exploratory Study of the Safety, Tolerability and Efficacy of Multiple Regimens of Natalizumab in Adult Subjects With Relapsing MS

Liege :

Safety and Efficacy Study OnabotulinumtoxinA for the Treatment of Urinary Incontinence in Multiple Sclerosis

Liège : Research Site

Avonex-evaluation of Quality of Life and Convenience in Belgian Patients - The AVAIL Study

Limburg : Research Site

Avonex-evaluation of Quality of Life and Convenience in Belgian Patients - The AVAIL Study

Luxembourg : Research Site

Avonex-evaluation of Quality of Life and Convenience in Belgian Patients - The AVAIL Study

Many Locations :

Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment

Many Locations :

Study Evaluating Betaferons® Safety and Tolerability In Pediatric Patients With Multiple Sclerosis

Melsbroek : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Oost-Vlaanderen : Research Site

Avonex-evaluation of Quality of Life and Convenience in Belgian Patients - The AVAIL Study

Overpelt : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Roeselare : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Sijsele : Novartis Investigative Site

Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND)

Sijsele-damme : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

West-Vlaanderen : Research Site

Avonex-evaluation of Quality of Life and Convenience in Belgian Patients - The AVAIL Study

Wilrijk : Research Site

Exploratory Study of the Safety, Tolerability and Efficacy of Multiple Regimens of Natalizumab in Adult Subjects With Relapsing MS

Bosnia and Herzegovina

Banja Luka : Synthon investigational site 486

Efficacy and Safety of GTR in Comparison to Copaxone®

Many Locations :

Noninterventional Study Assessing Cognitive Function and Physical Activity in People With Multiple Sclerosis

Many Locations :

Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment

Sarajevo : Synthon investigational site 487

Efficacy and Safety of GTR in Comparison to Copaxone®

Sarajewo : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

View More »

Tuzla : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Tuzla : Synthon investigational site 488

Efficacy and Safety of GTR in Comparison to Copaxone®

Brazil

Belo Horizonte : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Belo Horizonte : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Goiania : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Goiânia : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Joinville : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

View More »

Porto Alegre : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Porto Alegre : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Rio de Janeiro : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Rio de Janeiro : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Sao Paulo : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Bulgaria

Pleven : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Pleven : Synthon investigational site 207

Efficacy and Safety of GTR in Comparison to Copaxone®

Plovdiv : Synthon investigational site 206

Efficacy and Safety of GTR in Comparison to Copaxone®

Sofia : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Sofia : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

View More »

Sofia : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Sofia : Synthon investigational site 202

Efficacy and Safety of GTR in Comparison to Copaxone®

Sofia : Synthon investigational site 203

Efficacy and Safety of GTR in Comparison to Copaxone®

Sofia : Synthon investigational site 205

Efficacy and Safety of GTR in Comparison to Copaxone®

Sofia : Synthon investigational site 208

Efficacy and Safety of GTR in Comparison to Copaxone®

Sofia : XX

Phase 3 Study to Evaluate Efficacy and Safety of NU100 in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)

Varna : Synthon investigational site 201

Efficacy and Safety of GTR in Comparison to Copaxone®

Canada

Bracebridge : South Muskoka Medical Clinic

Study of Tysabri in Early Relapsing Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients

Burlington : Central Contact

Canadian Avonex PEN Productivity Study

Calgary : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Calgary : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Calgary : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

View More »

Edmonton : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Edmonton : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Edmonton : University of Alberta

Study of Tysabri in Early Relapsing Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients

Gatineau : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Gatineau : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Gatineau : Clinique Neuro-Outaouais

Cognitive Evolution in Tysabri Treated Multiple Sclerosis Patients

Gatineau : Research Site

Exploratory Study to Assess the Effect of Fampridine on Walking Ability and Balance in Patients With Multiple Sclerosis.

Greenfield Park : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Greenfield Park : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Greenfield Park : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Greenfield Park : Research Site

Exploratory Study to Assess the Effect of Fampridine on Walking Ability and Balance in Patients With Multiple Sclerosis.

Halifax : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Halifax : Research Site

Exploratory Study to Assess the Effect of Fampridine on Walking Ability and Balance in Patients With Multiple Sclerosis.

Halifax : Dalhousie MS Research Unit

Study of Tysabri in Early Relapsing Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients

Kingston : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

London : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

London : London Health Sciences Centre

Study of Tysabri in Early Relapsing Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients

Montreal : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Montreal : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Montreal : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Montreal : Research Site

Exploratory Study to Assess the Effect of Fampridine on Walking Ability and Balance in Patients With Multiple Sclerosis.

Montreal : McGill University - MNI

Study of Tysabri in Early Relapsing Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients

Montréal : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Ottawa : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Ottawa : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Ottawa : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Ottawa : The Ottawa Hospital

Study of Tysabri in Early Relapsing Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients

Saint John : Saint John Regional Hospital

Study of Tysabri in Early Relapsing Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients

Toronto : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Toronto : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Toronto : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Toronto : Sunnybrook Health Sciences Centre

Study of Tysabri in Early Relapsing Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients

Vancouver : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Vancouver : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Vancouver : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Vancouver : Vancouver Coastal Health: University of British Columbia Hospital

Effect of Aerobic Exercise on Side Effects of Disease Modifying Therapy With Subcutaneous Interferon-b1b in Patients With Multiple Sclerosis

Vancouver : MS Clinic UBC Hospital

Pharmacogenomics of Drug Safety in Multiple Sclerosis

Victoria :

Safety and Efficacy Study OnabotulinumtoxinA for the Treatment of Urinary Incontinence in Multiple Sclerosis

Winnipeg : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

China

Many locations :

China Betaferon Adherence, Coping and Nurse Support Study

Many Locations :

Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment

Nanjing : Nanjing University Medical College Affiliated Drum Tower Hospital

Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cell Therapy for Patients With Progressive Multiple Sclerosis and Neuromyelitis Optica

Colombia

Barranquilla : Novartis Investigative Site

Safety and Tolerability of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis

Bogotá : Novartis Investigative Site

Safety and Tolerability of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis

Many Locations :

Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment

Medellin : Novartis Investigative Site

Safety and Tolerability of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis

Croatia

Osijek : Synthon investigational site 477

Efficacy and Safety of GTR in Comparison to Copaxone®

Pula : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Varazdin : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Zagreb : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Zagreb : Synthon investigational site 475

Efficacy and Safety of GTR in Comparison to Copaxone®

View More »

Zagreb : Synthon investigational site 476

Efficacy and Safety of GTR in Comparison to Copaxone®

Zagreb : Synthon investigational site 478

Efficacy and Safety of GTR in Comparison to Copaxone®

Zagreb : XX

Phase 3 Study to Evaluate Efficacy and Safety of NU100 in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)

Czech Republic

Brno : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Brno : Synthon investigational site 217

Efficacy and Safety of GTR in Comparison to Copaxone®

Brno : Synthon investigational site 211

Efficacy and Safety of GTR in Comparison to Copaxone®

Brno : Fakultni nemocnice u sv. Anny v Brne

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Brno : Research Site

Safety and Tolerability Study of MEDI-551, a B-cell Depleting Agent, to Treat Relapsing-Remitting Multiple Sclerosis

View More »

Brno-bohunice : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Hradec Kralove : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Hradec Kralove : Novartis Investigative Site

A Study to Evaluate the Safety, Tolerability and Efficacy of AIN457 in Patients With Relapsing-remitting Multiple Sclerosis

Hradec Kralove : Fakultni nemocnice Hradec Kralove

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Jihlava : Nemocnice Jihlava, prispevkova organizace

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Jihlava : Research Site

Safety and Tolerability Study of MEDI-551, a B-cell Depleting Agent, to Treat Relapsing-Remitting Multiple Sclerosis

Katowice : Synthon investigational site 240

Efficacy and Safety of GTR in Comparison to Copaxone®

Many Locations :

Noninterventional Study Assessing Cognitive Function and Physical Activity in People With Multiple Sclerosis

Many Locations :

Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment

Olomouc : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Olomouc : Synthon investigational site 210

Efficacy and Safety of GTR in Comparison to Copaxone®

Olomouc :

Safety and Efficacy Study OnabotulinumtoxinA for the Treatment of Urinary Incontinence in Multiple Sclerosis

Ostrava : Synthon investigational site 212

Efficacy and Safety of GTR in Comparison to Copaxone®

Ostrava : Fakultni Nemocnice Ostrava

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Pardubice : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Praha : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Praha : Synthon investigational site 215

Efficacy and Safety of GTR in Comparison to Copaxone®

Praha : Synthon investigational site 216

Efficacy and Safety of GTR in Comparison to Copaxone®

Praha : Faculty Hospital Motol

Neurogenic Detrusor Overactivity Following Spinal Cord Injury or Multiple Sclerosis

Praha : THOMAYER Faculty Hospital

Neurogenic Detrusor Overactivity Following Spinal Cord Injury or Multiple Sclerosis

Praha 2 : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Praha 2 : Novartis Investigative Site

A Study to Evaluate the Safety, Tolerability and Efficacy of AIN457 in Patients With Relapsing-remitting Multiple Sclerosis

Praha 2 : Vseobecna fakultni nemocnice v Praze

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Praha 4 - Krc : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Teplice : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Teplice : Synthon investigational site 214

Efficacy and Safety of GTR in Comparison to Copaxone®

Zlin : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Denmark

Aarhus C : MS Clinic, Department of Neurology, Aarhus University Hospital

Multiple Sclerosis and Progressive Resistance Training

Aarhus C : Sport Science, Aarhus University

Multiple Sclerosis and Progressive Resistance Training

Arthus C : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Esbjerg : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Esbjerg : Research Site

A Single-blinded, Controlled, Multi-centre Study of Effects of Exercise in Patients With Multiple Sclerosis

View More »

Esbjerg : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

Glostrup : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Glostrup : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

København Ø : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Odense : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Sønderborg : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

Vejle : Research Site

A Single-blinded, Controlled, Multi-centre Study of Effects of Exercise in Patients With Multiple Sclerosis

Vejle : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

Viborg : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

Egypt

Many Locations :

Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment

Estonia

Kohtla-Jarve : Synthon investigational site 297

Efficacy and Safety of GTR in Comparison to Copaxone®

Many Locations :

Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment

Tallinn : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Tallinn : Synthon investigational site 296

Efficacy and Safety of GTR in Comparison to Copaxone®

Tallinn : Novartis Investigative Site

Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND)

View More »

Tallinn : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

Tartu : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Finland

Helsinki : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Helsinki : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Helsinki : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

Helsinski : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Jyväskylä : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

View More »

Jyväskylä : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

Many Locations :

Study Evaluating Betaferons® Safety and Tolerability In Pediatric Patients With Multiple Sclerosis

Tampere : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Tampere : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Tampere : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Tampere : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

Turku : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Turku : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Turku : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

France

Amiens cedex : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Angers : Novartis Investigative Site

Fingolimod -Response According to Coping - Evaluation

Bordeaux : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Bordeaux : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Bordeaux : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

View More »

Bordeaux : Service de Neurologie - Pôle des Neurosciences Cliniques, CHU de Bordeaux.

Randomised Controlled Clinical Trial of Cognitive Rehabilitation in Multiple Sclerosis

Bron : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Bron cedex : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Caen : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Clermont Ferrand : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Clermont-ferrand : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Creteil : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Dijon : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Garches : Hopital Raymond Poincaré

Neurogenic Detrusor Overactivity Following Spinal Cord Injury or Multiple Sclerosis

Lille : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Lille : Hopital HURIET

Neurogenic Detrusor Overactivity Following Spinal Cord Injury or Multiple Sclerosis

Lommé : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Lyon : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Lyon : Hôpital Lyon Sud -Hospices Civils de Lyon

Neurogenic Detrusor Overactivity Following Spinal Cord Injury or Multiple Sclerosis

Many Locations :

Noninterventional Study Assessing Cognitive Function and Physical Activity in People With Multiple Sclerosis

Many Locations :

Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment

Marseille : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Marseille : Hopital de la conception

Neurogenic Detrusor Overactivity Following Spinal Cord Injury or Multiple Sclerosis

Marseille :

Safety and Efficacy Study OnabotulinumtoxinA for the Treatment of Urinary Incontinence in Multiple Sclerosis

Marseille : La Timone University Hospital (APHM)

The Inflammatory Process and the Medical Imaging in Patients With an Inflammatory Disease of the Central Nervous System.

Marseille cedex 5 : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Montpellier : CHU Hôpital Gui de Chauliac Service de Neurologie B

A Multicentre Study of the Efficacy and Safety of Supplementary Treatment With Cholecalciferol in Patients With Relapsing Multiple Sclerosis Treated With Subcutaneous Interferon Beta-1a 44 µg 3 Times Weekly

Montpellier : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Montpellier : Novartis Investigative Site

FTY720 in Patients With Primary Progressive Multiple Sclerosis

Montpellier cedex 5 : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Nancy : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Nancy : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Nancy : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Nantes : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Nantes : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Nantes : CHU Hotel Dieu

Neurogenic Detrusor Overactivity Following Spinal Cord Injury or Multiple Sclerosis

Nice : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Nice : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Nimes : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Nimes : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Paris : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Paris : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Paris : Groupe Hospitalier La Pitié Salpetriere

Neurogenic Detrusor Overactivity Following Spinal Cord Injury or Multiple Sclerosis

Paris : Hopital Tenon

Neurogenic Detrusor Overactivity Following Spinal Cord Injury or Multiple Sclerosis

Paris : La Pitie-Salpaetriere Hospital (APHP)

The Inflammatory Process and the Medical Imaging in Patients With an Inflammatory Disease of the Central Nervous System.

Ploemeur : CMRRF Kerpape

Neurogenic Detrusor Overactivity Following Spinal Cord Injury or Multiple Sclerosis

Poissy : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Poissy : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Reims : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Reims : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Reims : Maison Blanche Hospital

The Inflammatory Process and the Medical Imaging in Patients With an Inflammatory Disease of the Central Nervous System.

Rennes : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Rennes : Rennes University Hospital

The Inflammatory Process and the Medical Imaging in Patients With an Inflammatory Disease of the Central Nervous System.

Rouen : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Rouen : CHU Rouen - Hopital Charles Nicolle

Neurogenic Detrusor Overactivity Following Spinal Cord Injury or Multiple Sclerosis

Strasbourg : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Strasbourg : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Strasbourg : Nouvel Hopital civil de Strasbourg

Neurogenic Detrusor Overactivity Following Spinal Cord Injury or Multiple Sclerosis

Toulouse : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Toulouse : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Toulouse : CHU Toulouse - Hopital Rangueil

Neurogenic Detrusor Overactivity Following Spinal Cord Injury or Multiple Sclerosis

Toulouse : Purpan Hospital

The Inflammatory Process and the Medical Imaging in Patients With an Inflammatory Disease of the Central Nervous System.

Toulouse cedex 9 : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Tourcoing : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Georgia

Tbilisi : Synthon investigational site 529

Efficacy and Safety of GTR in Comparison to Copaxone®

Tbilisi : Synthon investigational site 526

Efficacy and Safety of GTR in Comparison to Copaxone®

Tbilisi : Synthon investigational site 527

Efficacy and Safety of GTR in Comparison to Copaxone®

Tbilisi : Synthon investigational site 528

Efficacy and Safety of GTR in Comparison to Copaxone®

Tbilisi : Synthon investigational site 530

Efficacy and Safety of GTR in Comparison to Copaxone®

View More »

Tbilisi : XX

Phase 3 Study to Evaluate Efficacy and Safety of NU100 in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)

Germany

Aachen : Novartis Investigative Site

Effect of Physical ACtivity in Fingolimod Treated patiEnts (PACE) With Relapsing-remitting Multiple Sclerosis

Aachen : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Aalen : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Abensberg : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Achim : Novartis Investigative Site

Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression

View More »

Achim : Novartis Investigative Site

Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms

Achim : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Altenholz-Stift : Novartis Investigative Site

Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression

Altenholz-Stift : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Alzenau : Novartis Investigative Site

Effect of Physical ACtivity in Fingolimod Treated patiEnts (PACE) With Relapsing-remitting Multiple Sclerosis

Alzenau : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Asbach : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

Aschaffenburg : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Aschaffenburg : Novartis Investigative Site

Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression

Aschaffenburg : Novartis Investigative Site

Effect of Physical ACtivity in Fingolimod Treated patiEnts (PACE) With Relapsing-remitting Multiple Sclerosis

Aschaffenburg : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Augsburg : Novartis Investigative Site

Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression

Augsburg : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Bad Honnef : Novartis Investigative Site

Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression

Bad Honnef : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Bad Krozingen : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Bad Mergentheim : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Bad Mergentheim : Novartis Investigative Site

Effect of Physical ACtivity in Fingolimod Treated patiEnts (PACE) With Relapsing-remitting Multiple Sclerosis

Bad Mergentheim : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Bad Neustadt / Saale : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

Bad Saarow : Novartis Investigative Site

Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression

Bad Saarow : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Bad Wilbad : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Bad Wildbad : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Baesweiler : Novartis Investigative Site

Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression

Bamberg : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Bamberg : Novartis Investigative Site

Effect of Physical ACtivity in Fingolimod Treated patiEnts (PACE) With Relapsing-remitting Multiple Sclerosis

Bamberg : Novartis Investigative Site

Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms

Bamberg : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Bamberg : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

Bayreuth : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Bayreuth : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Bayreuth : Novartis Investigative Site

Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression

Berg : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Berlin : Charité Universitätsmedizin

A Phase IIa Study of NT-KO-003 for Multiple Sclerosis

Berlin : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Berlin : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Berlin : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Berlin : Novartis Investigative Site

Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression

Berlin : Novartis Investigative Site

Effect of Physical ACtivity in Fingolimod Treated patiEnts (PACE) With Relapsing-remitting Multiple Sclerosis

Berlin : Synthon investigational site 221

Efficacy and Safety of GTR in Comparison to Copaxone®

Berlin : St. Hedwig Hospital, Department of Urology

Efficacy of Clean Intermittent Catheterization in MS Patients With Bladder Dysfunction

Berlin : Novartis Investigative Site

Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND)

Berlin : Novartis Investigative Site

Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms

Berlin : Morphosys Investigative Site

Phase Ib Study to Evaluate MOR103 in Multiple Sclerosis

Berlin : GSK Investigational Site

Study to Assess Whether GSK239512 Can Remyelinate Lesions in Subjects With Relapsing Remitting Multiple Sclerosis

Berlin : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Berlin : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

Bielefeld : Novartis Investigative Site

Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression

Bielefeld : Novartis Investigative Site

Effect of Physical ACtivity in Fingolimod Treated patiEnts (PACE) With Relapsing-remitting Multiple Sclerosis

Bielefeld : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Böblingen : Novartis Investigative Site

Effect of Physical ACtivity in Fingolimod Treated patiEnts (PACE) With Relapsing-remitting Multiple Sclerosis

Böblingen : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Bochum : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Bochum : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Bochum : Novartis Investigative Site

Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression

Bochum : Novartis Investigative Site

Effect of Physical ACtivity in Fingolimod Treated patiEnts (PACE) With Relapsing-remitting Multiple Sclerosis

Bochum : Research Site

Exploratory Study of the Safety, Tolerability and Efficacy of Multiple Regimens of Natalizumab in Adult Subjects With Relapsing MS

Bochum : Research Site

Fampridine Pregnancy Exposure Registry

Bochum : Novartis Investigative Site

Pregnancy Registry Trial

Bochum : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Bogen : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Bonn : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Bonn : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Bottrop : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Bremen : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Bremerhaven : Novartis Investigative Site

Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression

Bremerhaven : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Buchholz : Novartis Investigative Site

Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression

Buchholz : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Butzbach : Novartis Investigative Site

Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression

Butzbach : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Celle : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Chemnitz : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Darmstadt : Please contact the Merck Communications Service for Recruiting locations

A Phase 4 Study to Assess the Impact of Patient Support Program on Health Related Quality of Life and Adherence in Subjects With Relapsing-Remitting Multiple Sclerosis Administered Rebif® With the RebiSmart™ Device

Dillingen : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Dortmund : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Dresden : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Dresden : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Dresden : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Dresden : Novartis Investigative Site

Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression

Dresden : Synthon investigational site 220

Efficacy and Safety of GTR in Comparison to Copaxone®

Dresden : Research Site

Exploratory Study of the Safety, Tolerability and Efficacy of Multiple Regimens of Natalizumab in Adult Subjects With Relapsing MS

Dresden : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Duesseldorf : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Duesseldorf : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Düren : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Düsseldorf : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Düsseldorf : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Düsseldorf : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

Eltville : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Emden : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Emmendingen : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Erbach : Novartis Investigative Site

Effect of Physical ACtivity in Fingolimod Treated patiEnts (PACE) With Relapsing-remitting Multiple Sclerosis

Erbach : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Erfurt : Novartis Investigative Site

Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression

Erfurt : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Erlangen : Novartis Investigative Site

Effect of Physical ACtivity in Fingolimod Treated patiEnts (PACE) With Relapsing-remitting Multiple Sclerosis

Erlangen : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

Essen : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Essen : Novartis Investigative Site

Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression

Essen : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Frankfurt : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Frankfurt : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Frankfurt : Novartis Investigative Site

Effect of Physical ACtivity in Fingolimod Treated patiEnts (PACE) With Relapsing-remitting Multiple Sclerosis

Frankfurt : Research Site

Exploratory Study of the Safety, Tolerability and Efficacy of Multiple Regimens of Natalizumab in Adult Subjects With Relapsing MS

Frankfurt : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Freiburg : Research Site

Exploratory Study of the Safety, Tolerability and Efficacy of Multiple Regimens of Natalizumab in Adult Subjects With Relapsing MS

Freiburg : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Freiburg : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

Fulda : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Gelnhausen : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Gelsenkirchen : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

GIEßEN : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Gilching : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Göttingen : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Grevenbroich : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Grevenbroich : Novartis Investigative Site

Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression

Grevenbroich : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Gummersbach : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Halle : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Halle (Saale) : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Hamburg : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Hamburg : Novartis Investigative Site

Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression

Hamburg : Novartis Investigative Site

Effect of Physical ACtivity in Fingolimod Treated patiEnts (PACE) With Relapsing-remitting Multiple Sclerosis

Hamburg : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Hamburg : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

Hannover : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Hannover : Novartis Investigative Site

Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression

Hannover : Synthon investigational site 224

Efficacy and Safety of GTR in Comparison to Copaxone®

Hannover : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Hannover : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

Heidelberg : Novartis Investigative Site

A 3-year Multi-center Study to Describe Changes of OCT Parameters Under Treatment With Gilenya®

Heidelberg : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Heidelberg : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Heidelberg : Novartis Investigative Site

Effect of Physical ACtivity in Fingolimod Treated patiEnts (PACE) With Relapsing-remitting Multiple Sclerosis

Heidelberg : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Heidenheim : Novartis Investigative Site

Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression

Heidenheim : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Hennigsdorf : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Herford : Novartis Investigative Site

Effect of Physical ACtivity in Fingolimod Treated patiEnts (PACE) With Relapsing-remitting Multiple Sclerosis

Herford : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Hoppegarten : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Itzehoe : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Jena : Synthon investigational site 227

Efficacy and Safety of GTR in Comparison to Copaxone®

Jena : Research Site

Exploratory Study of the Safety, Tolerability and Efficacy of Multiple Regimens of Natalizumab in Adult Subjects With Relapsing MS

Jena : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Juelich : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Kandel : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Kassel : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Kassel : Novartis Investigative Site

Effect of Physical ACtivity in Fingolimod Treated patiEnts (PACE) With Relapsing-remitting Multiple Sclerosis

Kassel : Novartis Investigative Site

Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND)

Kassel : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Kastellaun : Novartis Investigative Site

Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression

Kastellaun : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Kiel : Universitätsklinik Kiel

Neurogenic Detrusor Overactivity Following Spinal Cord Injury or Multiple Sclerosis

Klingenmünster : Novartis Investigative Site

Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression

Klingenmünster : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Koeln : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Koeln : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Köln : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Köln : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Köln : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

Königsbrück : Novartis Investigative Site

Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression

Krefeld : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Landshut : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Lappersdorf : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Leipzig : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Leipzig : Novartis Investigative Site

Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression

Leipzig : Novartis Investigative Site

Effect of Physical ACtivity in Fingolimod Treated patiEnts (PACE) With Relapsing-remitting Multiple Sclerosis

Leipzig : Novartis Investigative Site

Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms

Leipzig : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Leverkusen : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Lohr am Main : Novartis Investigative Site

Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression

Lohr am Main : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Ludwigshafen : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Lüneburg : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Lutherstadt Eisleben : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Magdeburg : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Mainz : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Mannheim : Novartis Investigative Site

Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression

Mannheim : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Many Locations :

Injection Management With Betaferon: Influence on Adherence, Patients Satisfaction and Health Related Outcomes (BETAPATH)

Many Locations :

Investigating the Relationship Between Sleep, Quality of Life,Other Disorders and Therapies in MS Patients on Betaferon

Many Locations :

Noninterventional Study Assessing Cognitive Function and Physical Activity in People With Multiple Sclerosis

Many Locations :

Study Evaluating Betaferons® Safety and Tolerability In Pediatric Patients With Multiple Sclerosis

Marburg : Research Site

Exploratory Study of the Safety, Tolerability and Efficacy of Multiple Regimens of Natalizumab in Adult Subjects With Relapsing MS

Marburg : Novartis Investigative Site

Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms

Merzig : Novartis Investigative Site

Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression

Mittweida : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Mönchengladbach : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Muenchen : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Muenchen : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Muenchen : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Muenster : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Muenster : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Muenster : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Mülheim : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

München : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

München : Novartis Investigative Site

Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression

München : Novartis Investigative Site

Effect of Physical ACtivity in Fingolimod Treated patiEnts (PACE) With Relapsing-remitting Multiple Sclerosis

München : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Munich : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Münster : Klinik und Poliklinik für Neurologie

A Phase IIa Study of NT-KO-003 for Multiple Sclerosis

Münster : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Münster : Novartis Investigative Site

Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression

Münster : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Münster : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

Nagold : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Neuberg : Research Site

An Observational Study to Collect Information on Safety and to Document the Drug Utilization of Fampyra® When Used In Routine Medical Practice

Neuburg : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Neuburg : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Neunkirchen : Städtisches Klinikum Neunkirchen

Neurogenic Detrusor Overactivity Following Spinal Cord Injury or Multiple Sclerosis

Neuruppin : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Neusäß : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Neu-Ulm : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Nienburg : Novartis Investigative Site

Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression

Nümbrecht : Novartis Investigative Site

Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression

Oberhausen : Novartis Investigative Site

Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression

Oldenburg : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Oldenburg : Novartis Investigative Site

Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression

Oldenburg : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Osnabrück : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Osnabrück : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

Ostfildern : Novartis Investigative Site

Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression

Ostfildern : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Paderborn : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Pforzheim : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Potsdam : Novartis Investigative Site

Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression

Potsdam : Novartis Investigative Site

Effect of Physical ACtivity in Fingolimod Treated patiEnts (PACE) With Relapsing-remitting Multiple Sclerosis

Potsdam : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Prien : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Prien : Novartis Investigative Site

Effect of Physical ACtivity in Fingolimod Treated patiEnts (PACE) With Relapsing-remitting Multiple Sclerosis

Prien : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Quakenbrück : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Regensburg : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Regensburg : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Regensburg : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

Remscheid : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Roesrath : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Rostock : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Rostock : Synthon investigational site 222

Efficacy and Safety of GTR in Comparison to Copaxone®

Rostock : Novartis Investigative Site

Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms

Rostock : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

Rüdersdorf : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Schwalmstadt-Treysa : Novartis Investigative Site

Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression

Siegen : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Siegen : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Siegen : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

Singen : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Sinsheim : Novartis Investigative Site

Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression

Sinsheim : Novartis Investigative Site

Effect of Physical ACtivity in Fingolimod Treated patiEnts (PACE) With Relapsing-remitting Multiple Sclerosis

Sinsheim : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Stade : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Stadtroda : Novartis Investigative Site

Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression

Stadtroda : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Stuttgart : Novartis Investigative Site

Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression

Stuttgart : Novartis Investigative Site

Effect of Physical ACtivity in Fingolimod Treated patiEnts (PACE) With Relapsing-remitting Multiple Sclerosis

Stuttgart : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Telgte : Novartis Investigative Site

Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression

Telgte : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Teupitz : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Teupitz : Novartis Investigative Site

Effect of Physical ACtivity in Fingolimod Treated patiEnts (PACE) With Relapsing-remitting Multiple Sclerosis

Teupitz : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Troisdorf : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Tübingen : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Tübingen : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Tübingen : Novartis Investigative Site

Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression

Tübingen : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Tuebingen : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

ULM : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

ULM : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Ulm : Research Site

Exploratory Study of the Safety, Tolerability and Efficacy of Multiple Regimens of Natalizumab in Adult Subjects With Relapsing MS

Ulm : Novartis Investigative Site

Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms

Ulm : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Unterhaching : Novartis Investigative Site

Effect of Physical ACtivity in Fingolimod Treated patiEnts (PACE) With Relapsing-remitting Multiple Sclerosis

Unterhaching : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Wasserburg : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Weil am Rhein : Novartis Investigative Site

Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression

Wendlingen : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Wermsdorf : Novartis Investigative Site

Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression

Wermsdorf : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Westerstede : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Westerstede : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Wiesbaden : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Wiesbaden : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Wolfratshausen : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Würzburg : Novartis Investigative Site

Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms

Würzburg : Novartis Investigative Site

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Zwickau : Novartis Investigative Site

Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression

Greece

Athens : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Many Locations :

Noninterventional Study Assessing Cognitive Function and Physical Activity in People With Multiple Sclerosis

Thessaloniki : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Hungary

Budapest : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Budapest : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Budapest : Novartis Investigative Site

Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND)

Budapest : XX

Phase 3 Study to Evaluate Efficacy and Safety of NU100 in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)

Esztergom : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

View More »

Esztergom : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Many Locations :

Noninterventional Study Assessing Cognitive Function and Physical Activity in People With Multiple Sclerosis

Pécs : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Szeged : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Veszprem : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Ireland

Dublin : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Dublin : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Israel

Ashkelon : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Haifa : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Jerusalem : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Many Locations :

Noninterventional Study Assessing Cognitive Function and Physical Activity in People With Multiple Sclerosis

Many Locations :

Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment

View More »

Petach Tikva : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Ramat Gan : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Ramat-gan : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Safed : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Tel Aviv : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Italy

Acquaviva Delle Fonti : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Ancona : Research Site

Exploratory Study to Assess the Effect of Fampridine on Walking Ability and Balance in Patients With Multiple Sclerosis.

Ancona : Novartis Investigative Site

Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms

Ancona : Novartis Investigative Site

Patients With RRMS:Candidates for MS Therapy Change

Baggiovara : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

View More »

Bari : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Bari : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Bari : Novartis Investigative Site

Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms

Barletta : Novartis Investigative Site

Patients With RRMS:Candidates for MS Therapy Change

Bergamo : Novartis Investigative Site

Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms

Biella : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Biella : Novartis Investigative Site

Patients With RRMS:Candidates for MS Therapy Change

Bolzano : Novartis Investigative Site

Patients With RRMS:Candidates for MS Therapy Change

Brescia : Research Site

Exploratory Study to Assess the Effect of Fampridine on Walking Ability and Balance in Patients With Multiple Sclerosis.

Cagliari : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Caltanissetta : Novartis Investigative Site

Patients With RRMS:Candidates for MS Therapy Change

Catania : Synthon investigational site 238

Efficacy and Safety of GTR in Comparison to Copaxone®

Catania : Novartis Investigative Site

Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms

Catania : Novartis Investigative Site

Patients With RRMS:Candidates for MS Therapy Change

Catanzaro : Novartis Investigative Site

Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms

Cefalu : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Cefalu : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Cefalu : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

Cefalù : Novartis Investigative Site

Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms

Chieti : Research Site

Exploratory Study of the Safety, Tolerability and Efficacy of Multiple Regimens of Natalizumab in Adult Subjects With Relapsing MS

Chieti : Novartis Investigative Site

Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms

Como : Novartis Investigative Site

Patients With RRMS:Candidates for MS Therapy Change

Coppito : Synthon investigational site 234

Efficacy and Safety of GTR in Comparison to Copaxone®

Cuneo : Novartis Investigative Site

Patients With RRMS:Candidates for MS Therapy Change

Empoli : Novartis Investigative Site

Patients With RRMS:Candidates for MS Therapy Change

Fidenza : Novartis Investigative Site

Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms

Firenze : Novartis Investigative Site

Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms

Firenze : Ospedale Careggi

Neurogenic Detrusor Overactivity Following Spinal Cord Injury or Multiple Sclerosis

Florence : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Foggia : Novartis Investigative Site

Patients With RRMS:Candidates for MS Therapy Change

Gallarate : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Gallarate : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Gallarate : Novartis Investigative Site

Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms

Genova : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Genova : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Genova : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Genova : Novartis Investigative Site

Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms

Imperia : Novartis Investigative Site

Patients With RRMS:Candidates for MS Therapy Change

L'Aquila : Novartis Investigative Site

Patients With RRMS:Candidates for MS Therapy Change

Lecce : Novartis Investigative Site

Patients With RRMS:Candidates for MS Therapy Change

Legnago : Novartis Investigative Site

Patients With RRMS:Candidates for MS Therapy Change

Livorno : Novartis Investigative Site

Patients With RRMS:Candidates for MS Therapy Change

Many Locations :

Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment

Messina : Novartis Investigative Site

Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms

Messina : Novartis Investigative Site

Patients With RRMS:Candidates for MS Therapy Change

Milan : Institute of Experimental Neurology

Neurophysiological Study of Sativex in Multiple Sclerosis (MS) Spasticity

Milano : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Milano : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Milano : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Milano : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Milano : Synthon investigational site 233

Efficacy and Safety of GTR in Comparison to Copaxone®

Milano : Novartis Investigative Site

Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms

Milano : Novartis Investigative Site

Patients With RRMS:Candidates for MS Therapy Change

Modena : Novartis Investigative Site

Patients With RRMS:Candidates for MS Therapy Change

Montichiari : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Montichiari : Novartis Investigative Site

Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms

Monza : Novartis Investigative Site

Patients With RRMS:Candidates for MS Therapy Change

Naples : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Naples : Investigational Site

Dietary Supplement of Curcumin in Subjects With Active Relapsing Multiple Sclerosis Treated With Subcutaneous Interferon Beta 1a

Napoli : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Napoli : Novartis Investigative Site

Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms

Novara : Novartis Investigative Site

Patients With RRMS:Candidates for MS Therapy Change

Orbassano : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Padova : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Palermo : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Palermo : Novartis Investigative Site

Patients With RRMS:Candidates for MS Therapy Change

Pavia : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Pavia : Novartis Investigative Site

Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms

Perugia : Novartis Investigative Site

Patients With RRMS:Candidates for MS Therapy Change

Pisa : Novartis Investigative Site

Patients With RRMS:Candidates for MS Therapy Change

Pozzilli : Novartis Investigative Site

Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms

Reggio Calabria : Novartis Investigative Site

Patients With RRMS:Candidates for MS Therapy Change

Roma : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Roma : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Roma : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Roma : Research Site Updated

Dose-finding Study of MT-1303

Roma : Novartis Investigative Site

Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms

Roma : Novartis Investigative Site

Patients With RRMS:Candidates for MS Therapy Change

Rome : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Rome : XX

Phase 3 Study to Evaluate Efficacy and Safety of NU100 in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)

San Donato Milanese : Novartis Investigative Site

Patients With RRMS:Candidates for MS Therapy Change

Torrette Di Ancona : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Trieste : Novartis Investigative Site

Patients With RRMS:Candidates for MS Therapy Change

Verona : Novartis Investigative Site

Patients With RRMS:Candidates for MS Therapy Change

Japan

Chiba, : Research Site

BG00002 Study in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)

Chiba, : Research Site

Extension Study to Evaluate Safety and Efficacy of BG00002 in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis

Fukuoka, : Research Site

BG00002 Study in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)

Fukuoka, : Research Site

Extension Study to Evaluate Safety and Efficacy of BG00002 in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis

Hiroshima, : Research Site

BG00002 Study in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)

View More »

Hiroshima, : Research Site

Extension Study to Evaluate Safety and Efficacy of BG00002 in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis

Kawagoe, : Research Site

BG00002 Study in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)

Kawagoe, : Research Site

Extension Study to Evaluate Safety and Efficacy of BG00002 in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis

Kodaira, : University of British Columbia

BG00002 Study in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)

Kodaira, : Research Site

Extension Study to Evaluate Safety and Efficacy of BG00002 in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis

Kyoto, : Research Site

BG00002 Study in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)

Kyoto, : London Health Sciences Centre

BG00002 Study in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)

Kyoto, : Research Site

Extension Study to Evaluate Safety and Efficacy of BG00002 in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis

Morioka, : Research Site

BG00002 Study in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)

Morioka, : Research Site

Extension Study to Evaluate Safety and Efficacy of BG00002 in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis

Niigata, : Research Site

BG00002 Study in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)

Niigata, : Research Site

Extension Study to Evaluate Safety and Efficacy of BG00002 in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis

Osaka, : Research Site

BG00002 Study in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)

Osaka, : Univ of Calgary / Foothills MC

BG00002 Study in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)

Osaka, : Research Site

Extension Study to Evaluate Safety and Efficacy of BG00002 in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis

Sapporo, : Research Site

BG00002 Study in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)

Sapporo, : Research Site

Extension Study to Evaluate Safety and Efficacy of BG00002 in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis

Sendai, : Research Site

BG00002 Study in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)

Sendai, : Research Site

Extension Study to Evaluate Safety and Efficacy of BG00002 in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis

Suita, : Research Site

BG00002 Study in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)

Suita, : Research Site

Extension Study to Evaluate Safety and Efficacy of BG00002 in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis

Tokorozawa, : Research Site

BG00002 Study in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)

Tokorozawa, : Research Site

Extension Study to Evaluate Safety and Efficacy of BG00002 in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis

Tokyo, : Research Site

BG00002 Study in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)

Tokyo, : Research Site

Extension Study to Evaluate Safety and Efficacy of BG00002 in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis

Tsukuba, : Research Site

BG00002 Study in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)

Tsukuba, : Research Site

Extension Study to Evaluate Safety and Efficacy of BG00002 in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis

Ube, : Research Site

BG00002 Study in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)

Ube, : Research Site

Extension Study to Evaluate Safety and Efficacy of BG00002 in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis

Yokohama, : Research Site

BG00002 Study in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)

Yokohama, : Research Site

Extension Study to Evaluate Safety and Efficacy of BG00002 in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis

Jordan

Amman : Novartis Investigative Site

Safety and Tolerability of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis

Many Locations :

Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment

Kazakhstan

Many Locations :

Noninterventional Study Assessing Cognitive Function and Physical Activity in People With Multiple Sclerosis

Korea, Republic of

Many Locations :

Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment

Kuwait

Many Locations :

Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment

Latvia

Riga : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Riga : Novartis Investigative Site

Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND)

Riga : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

Lebanon

Beirut : XX

Phase 3 Study to Evaluate Efficacy and Safety of NU100 in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)

Many Locations :

Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment

Libyan Arab Jamahiriya

Many Locations :

Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment

Lithuania

Kaunas : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Kaunas : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Kaunas : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

Klaipeda : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Klaipeda : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

View More »

Klaipeda : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

Siauliai : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Vilnius : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Malaysia

Kuala Lumpur : Novartis Investigative Site

Safety and Tolerability of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis

Penang : Novartis Investigative Site

Safety and Tolerability of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis

Mexico

Aguascalientes : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Aguascalientes : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Chihuahua : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Chihuahua : Synthon investigational site 518

Efficacy and Safety of GTR in Comparison to Copaxone®

Culiacan : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

View More »

Guadalajara : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Guadalajara : Synthon investigational site 516

Efficacy and Safety of GTR in Comparison to Copaxone®

Many Locations :

Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment

Mexico : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Mexico : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Mexico : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Mexico : Novartis Investigative Site

Safety and Tolerability of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis

Mexico City : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Mexico City : Synthon investigational site 514

Efficacy and Safety of GTR in Comparison to Copaxone®

Monterrey : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Monterrey : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Monterrey : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Monterrey : Novartis Investigative Site

Safety and Tolerability of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis

Morelia : Synthon investigational site 515

Efficacy and Safety of GTR in Comparison to Copaxone®

San Luis de Potosi : Synthon investigational site 522

Efficacy and Safety of GTR in Comparison to Copaxone®

San Luis Potosí : Novartis Investigative Site

Safety and Tolerability of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis

Tijuana : Hospital Angeles

Study to Assess the Safety and Effects of Autologous Adipose-Derived Stromal Cells Delivered Into Patients With Multiple Sclerosis

Tlalnepantla : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Moldova, Republic of

Chisinau : Synthon investigational site 548

Efficacy and Safety of GTR in Comparison to Copaxone®

Chisinau : Synthon investigational site 549

Efficacy and Safety of GTR in Comparison to Copaxone®

Chisinau : Synthon investigational site 550

Efficacy and Safety of GTR in Comparison to Copaxone®

Chisinau : Synthon investigational site 547

Efficacy and Safety of GTR in Comparison to Copaxone®

Netherlands

Amsterdam : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Amsterdam : Novartis Investigative Site

Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND)

Amsterdam : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

Breda : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Breda : Amphia Ziekenhuis

Optical Coherence Tomography: Glatiramer in Clinically Isolated Syndrome or Early Relapsing Remitting Multiple Sclerosis (MS)

View More »

Eindhoven : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

Gouda : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

Hertogenbosch : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Hoorn : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Leeuwarden : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

Many Locations :

Noninterventional Study Assessing Cognitive Function and Physical Activity in People With Multiple Sclerosis

Many Locations :

Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment

Nieuwegein : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Nieuwegein : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Nieuwegein : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

Nijmegen : UMC ST Radboud Nijmegen, Department of Urology

Efficacy of Clean Intermittent Catheterization in MS Patients With Bladder Dysfunction

Rotterdam : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Sittard : Maasland Ziekenhuis

Optical Coherence Tomography: Glatiramer in Clinically Isolated Syndrome or Early Relapsing Remitting Multiple Sclerosis (MS)

Sittard : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

Sittard-Geleen : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Sittard-geleen : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Sittard-Geleen : Research Site

Exploratory Study to Assess the Effect of Fampridine on Walking Ability and Balance in Patients With Multiple Sclerosis.

New Zealand

Hamilton : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Hamilton : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Many Locations :

Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment

Wellington : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Norway

Bergen : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Bergen : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

Lørenskog : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

Many Locations :

Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment

Molde : Molde Hospital

An Observational Study to Collect Information on Safety and to Document the Drug Utilization of Fampyra® When Used In Routine Medical Practice

View More »

Oslo : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Oslo : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

Stavanger : Stavanger University Hospital

An Observational Study to Collect Information on Safety and to Document the Drug Utilization of Fampyra® When Used In Routine Medical Practice

Tønsberg : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Panama

Panama City : Novartis Investigative Site

Safety and Tolerability of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis

Peru

Bellavista : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Jesus Maria : Novartis Investigative Site

Safety and Tolerability of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis

La Perla : Novartis Investigative Site

Safety and Tolerability of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis

Lima : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

San Isidro : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

View More »

San Isidro : Novartis Investigative Site

Safety and Tolerability of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis

Poland

Bialystok : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Bialystok : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Bialystok : Synthon investigational site 244

Efficacy and Safety of GTR in Comparison to Copaxone®

Bydgoszcz : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Czeladz : Szpital Powiatowy w Czeladzi

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

View More »

Gdansk : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Gdansk : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Gdansk : Morphosys Investigative Site

Phase Ib Study to Evaluate MOR103 in Multiple Sclerosis

Jaroslaw : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Jaroslaw : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Katowice : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Katowice : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Katowice : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Katowice : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Katowice : Synthon investigational site 241

Efficacy and Safety of GTR in Comparison to Copaxone®

Katowice : Synthon investigational site 245

Efficacy and Safety of GTR in Comparison to Copaxone®

Katowice : Synthon investigational site 242

Efficacy and Safety of GTR in Comparison to Copaxone®

Katowice : Diagnomed Clinical Research Sp. z.o.o.

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Katowice : Niepubliczny Zaklad Opieki Zdrowotnej NEURO-MEDIC

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Katowice : Niepubliczny Zaklad Opieki Zdrowotnej PROFILAKTYKA

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Katowice : Research Site

Safety and Tolerability Study of MEDI-551, a B-cell Depleting Agent, to Treat Relapsing-Remitting Multiple Sclerosis

Konskie : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Konskie : Zespol Opieki Zdrowotnej w Konskich

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Krakow : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Krakow : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Krakow : Research Site

Safety and Tolerability Study of MEDI-551, a B-cell Depleting Agent, to Treat Relapsing-Remitting Multiple Sclerosis

Lodz : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Lodz : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Lodz : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Lodz : Synthon investigational site 247

Efficacy and Safety of GTR in Comparison to Copaxone®

Lublin : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Lublin : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Lublin : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Lublin : Synthon investigational site 251

Efficacy and Safety of GTR in Comparison to Copaxone®

Many Locations :

Assessment of Strategies for the Management of Flu-like Symptoms in MS Patients Commencing Treatment With Betaferon (INFLUENCE)

Olsztyn : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Olsztyn : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Olsztyn : Synthon investigational site 243

Efficacy and Safety of GTR in Comparison to Copaxone®

Plewiska : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Plewiska : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Plewiska : Specjalistyczny Gabinet Neurologiczny

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Poznan : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Poznan : Synthon investigational site 248

Efficacy and Safety of GTR in Comparison to Copaxone®

Poznan : Morphosys Investigative Site

Phase Ib Study to Evaluate MOR103 in Multiple Sclerosis

Poznan : Niepubliczny Zaklad Opieki Zdrowotnej NEURO-KARD Ilkowski i Partnerzy Spolka Partnerska Lekarzy

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Szczecin : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Szczecin : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Szczecin : Osrodek Badan Klinicznych Indywidualnej Specjalistycznej Praktyki Lekarskiej

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Szczecin : Research Site

Safety and Tolerability Study of MEDI-551, a B-cell Depleting Agent, to Treat Relapsing-Remitting Multiple Sclerosis

Warsaw : XX

Phase 3 Study to Evaluate Efficacy and Safety of NU100 in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)

Warszawa : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Warszawa : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Warszawa : Synthon investigational site 246

Efficacy and Safety of GTR in Comparison to Copaxone®

Warszawa : NZOZ Centrum Medyczne Mazovia

Neurogenic Detrusor Overactivity Following Spinal Cord Injury or Multiple Sclerosis

Warszawa-Miedzylesie : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Wroclaw : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Wroclaw : Synthon investigational site 249

Efficacy and Safety of GTR in Comparison to Copaxone®

Portugal

Almada : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Almada : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Amadora : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Braga : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Coimbra : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

View More »

Coimbra : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Lisboa : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Lisboa : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Lisbon : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

Many Locations :

Noninterventional Study Assessing Cognitive Function and Physical Activity in People With Multiple Sclerosis

Many Locations :

Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment

Porto : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Porto : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

Puerto Rico

Guaynabo : Caribbean Center for Clinical Research, Inc.

Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies

Romania

Bucharest : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Bucharest : Synthon investigational site 260

Efficacy and Safety of GTR in Comparison to Copaxone®

Bucharest : Synthon investigational site 264

Efficacy and Safety of GTR in Comparison to Copaxone®

Bucharest : Synthon investigational site 262

Efficacy and Safety of GTR in Comparison to Copaxone®

Bucharest : Synthon investigational site 263

Efficacy and Safety of GTR in Comparison to Copaxone®

View More »

Campulung : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Cluj-Napoca : Synthon investigational site 266

Efficacy and Safety of GTR in Comparison to Copaxone®

Targu Mures : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Timisoara : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Russian Federation

Arkhangelsk : Synthon investigational site 438

Efficacy and Safety of GTR in Comparison to Copaxone®

Barnaul : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Barnaul : Synthon investigational site 435

Efficacy and Safety of GTR in Comparison to Copaxone®

Barnaul : Novartis Investigative Site

Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg (EPOC)

Belgorod : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

View More »

Belgorod : Synthon investigational site 437

Efficacy and Safety of GTR in Comparison to Copaxone®

Belgorod : Novartis Investigative Site

Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg (EPOC)

Ekaterinburg : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Ekaterinburg : Synthon investigational site 431

Efficacy and Safety of GTR in Comparison to Copaxone®

Kaluga : Synthon investigational site 445

Efficacy and Safety of GTR in Comparison to Copaxone®

Kazan : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Kazan : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Kazan : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Kazan : Synthon investigational site 427

Efficacy and Safety of GTR in Comparison to Copaxone®

Kazan : Novartis Investigative Site

Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg (EPOC)

Kemerovo : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Kemerovo : Synthon investigational site 432

Efficacy and Safety of GTR in Comparison to Copaxone®

Kemerovo : Novartis Investigative Site

Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg (EPOC)

Khanty-Mantiysk : Novartis Investigative Site

Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg (EPOC)

Kirov : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Kirov : Synthon investigational site 447

Efficacy and Safety of GTR in Comparison to Copaxone®

Kirov : Novartis Investigative Site

Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg (EPOC)

Krasnodar : Novartis Investigative Site

Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg (EPOC)

Krasnoyarsk : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Kursk : Novartis Investigative Site

Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg (EPOC)

Lipetsk : Synthon investigational site 446

Efficacy and Safety of GTR in Comparison to Copaxone®

Moscow : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Moscow : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Moscow : Synthon investigational site 571

Efficacy and Safety of GTR in Comparison to Copaxone®

Moscow : Novartis Investigative Site

Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg (EPOC)

Moscow : XX

Phase 3 Study to Evaluate Efficacy and Safety of NU100 in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)

N.Novgorod : Novartis Investigative Site

Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg (EPOC)

Nizhniy Novgorod : Synthon investigational site 428

Efficacy and Safety of GTR in Comparison to Copaxone®

Nizhniy Novgorod : Synthon investigational site 429

Efficacy and Safety of GTR in Comparison to Copaxone®

Nizhniy Novgorod : Novartis Investigative Site

Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg (EPOC)

Nizhny Novgorod : Novartis Investigative Site

Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg (EPOC)

Nizniy Novgorod : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Novosibirsk : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Novosibirsk : Synthon investigational site 434

Efficacy and Safety of GTR in Comparison to Copaxone®

Novosibirsk : Synthon investigational site 442

Efficacy and Safety of GTR in Comparison to Copaxone®

Novosibirsk : Novartis Investigative Site

Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg (EPOC)

Penza : Synthon investigational site 444

Efficacy and Safety of GTR in Comparison to Copaxone®

Perm : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Perm : Novartis Investigative Site

Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg (EPOC)

Pyatigorsk : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Pyatigorsk : Synthon investigational site 433

Efficacy and Safety of GTR in Comparison to Copaxone®

Samara : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Samara : Synthon investigational site 424

Efficacy and Safety of GTR in Comparison to Copaxone®

Saransk : Novartis Investigative Site

Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg (EPOC)

Saratov : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Saratov : Novartis Investigative Site

Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg (EPOC)

Smolensk : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Smolensk : Synthon investigational site 420

Efficacy and Safety of GTR in Comparison to Copaxone®

Smolensk : Novartis Investigative Site

Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg (EPOC)

St. Petersburg : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

St. Petersburg : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

St. Petersburg : Novartis Investigative Site

Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg (EPOC)

St.Petersburg : Synthon investigational site 430

Efficacy and Safety of GTR in Comparison to Copaxone®

St.Petersburg : Synthon investigational site 426

Efficacy and Safety of GTR in Comparison to Copaxone®

St.Petersburg : Synthon investigational site 421

Efficacy and Safety of GTR in Comparison to Copaxone®

St.Petersburg : Synthon investigational site 440

Efficacy and Safety of GTR in Comparison to Copaxone®

Tomsk : Synthon investigational site 422

Efficacy and Safety of GTR in Comparison to Copaxone®

Tomsk : Novartis Investigative Site

Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg (EPOC)

Tumen : Novartis Investigative Site

Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg (EPOC)

Tver : Synthon investigational site 441

Efficacy and Safety of GTR in Comparison to Copaxone®

Tver : Novartis Investigative Site

Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg (EPOC)

Tyumen : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Tyumen : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Tyumen : Synthon investigational site 425

Efficacy and Safety of GTR in Comparison to Copaxone®

Ufa : Synthon investigational site 423

Efficacy and Safety of GTR in Comparison to Copaxone®

Ufa : Novartis Investigative Site

Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg (EPOC)

Ulyanovsk : Novartis Investigative Site

Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg (EPOC)

Volgograd : Synthon investigational site 443

Efficacy and Safety of GTR in Comparison to Copaxone®

Yaroslavl : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Yaroslavl : Novartis Investigative Site

Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg (EPOC)

Saudi Arabia

Many Locations :

Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment

Serbia

Belgrade : Synthon investigational site 451

Efficacy and Safety of GTR in Comparison to Copaxone®

Belgrade : XX

Phase 3 Study to Evaluate Efficacy and Safety of NU100 in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)

Kragujevac : Synthon investigational site 453

Efficacy and Safety of GTR in Comparison to Copaxone®

Novi Sad : Synthon investigational site 452

Efficacy and Safety of GTR in Comparison to Copaxone®

Slovakia

Banska Bystrica : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Bratislava : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Levoca : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Many Locations :

Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment

Martin : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

View More »

Nitra : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Zilina : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Slovenia

Many Locations :

Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment

South Africa

Cape Town : Synthon investigational site 501

Efficacy and Safety of GTR in Comparison to Copaxone®

Durban : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Durban : Synthon investigational site 505

Efficacy and Safety of GTR in Comparison to Copaxone®

Pretoria : Synthon investigational site 502

Efficacy and Safety of GTR in Comparison to Copaxone®

Spain

Alicante : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Alicante : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Badalona : Hospital Germans Trias i Pujol

A Phase IIa Study of NT-KO-003 for Multiple Sclerosis

Badalona : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Barcelona : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

View More »

Barcelona : Hospital de la Santa Creu i Sant Pau

A Phase 2b/3 Study to Compare Efficacy and Safety of Masitinib to Placebo in the Treatment of Patients With Primary Progressive or Relapse-free Secondary Progressive Multiple Sclerosis

Barcelona : Hospital del Mar

A Phase IIa Study of NT-KO-003 for Multiple Sclerosis

Barcelona : Hospital Clinic i Provincial

A Phase IIa Study of NT-KO-003 for Multiple Sclerosis

Barcelona : Hospital Vall d'Hebrón

A Phase IIa Study of NT-KO-003 for Multiple Sclerosis

Barcelona : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Barcelona : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Barcelona : Novartis Investigative Site

Efficacy of Fingolimod in de Novo Patients Versus Fingolimod in Patients Previously Treated With a First Line Disease Modifying Therapy

Barcelona : Novartis Investigative Site

Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND)

Barcelona : XX

Phase 3 Study to Evaluate Efficacy and Safety of NU100 in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)

Barcelona : Hospital del Mar

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Barcelona : Hospital Vall D´Hebron

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Bilbao : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

El Palmar : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

El Palmar : Hospital Universitario Virgen de la Arrixaca

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Girona : Hospital Universitari Josep Trueta

A Phase IIa Study of NT-KO-003 for Multiple Sclerosis

Girona : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Girona : Research Site

Exploratory Study of the Safety, Tolerability and Efficacy of Multiple Regimens of Natalizumab in Adult Subjects With Relapsing MS

Girona : Hospital Universitari de Girona Dr. Josep Trueta

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

L'hospitalet de Llobregat : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Madrid : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Madrid : Hospital Universitario 12 de Octubre

A Phase IIa Study of NT-KO-003 for Multiple Sclerosis

Madrid : Hospital Universitario La Princesa

A Phase IIa Study of NT-KO-003 for Multiple Sclerosis

Madrid : Hospital Universitario La Paz

A Phase IIa Study of NT-KO-003 for Multiple Sclerosis

Madrid : Hospital Universitario Puerta del Hierro

A Phase IIa Study of NT-KO-003 for Multiple Sclerosis

Madrid : Hospital Clínico San Carlos

A Phase IIa Study of NT-KO-003 for Multiple Sclerosis

Madrid : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Madrid : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Madrid : Research Site Updated

Dose-finding Study of MT-1303

Majadahonda : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Malaga : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Malaga : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Malaga : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Málaga : Hospital Regional Universitario Carlos Haya

A Phase IIa Study of NT-KO-003 for Multiple Sclerosis

San Sebastian : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Santa Cruz de Tenerife : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Santiago de Compostela : Complexo Hospitalario Universitario de Santiago

A Phase IIa Study of NT-KO-003 for Multiple Sclerosis

Santiago de Compostela : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Sevilla : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Sevilla : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Sevilla : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Sevilla : Hospital Universitario Vírgen Macarena

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Valencia : Hospital Universitario La Fe

A Phase IIa Study of NT-KO-003 for Multiple Sclerosis

Valencia : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Vigo : Hospital Xeral Vigo

A Phase IIa Study of NT-KO-003 for Multiple Sclerosis

Sweden

Göteborg : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Göteborg : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Göteborg : Research Site

Exploratory Study to Assess the Effect of Fampridine on Walking Ability and Balance in Patients With Multiple Sclerosis.

Göteborg : Novartis Investigative Site

OL, Single-arm Extension Study to the Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5 mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis

Örebro : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

View More »

Stockholm : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Stockholm : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Stockholm : Research Site

Exploratory Study to Assess the Effect of Fampridine on Walking Ability and Balance in Patients With Multiple Sclerosis.

Stockholm : Novartis Investigative Site

OL, Single-arm Extension Study to the Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5 mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis

Umeå : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Umeå : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Switzerland

Basel : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Basel : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Basel : University Hospital Basel

Safety Study of GNbAC1 in Multiple Sclerosis Patients

Bern : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

Geneva : Hopitaux Universitaires de Genève - HUG

Safety Study of GNbAC1 in Multiple Sclerosis Patients

View More »

Lausanne : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

Lugano : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Lugano : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Lugano : Ospedale Regionale di Lugano - Civico

Natalizumab De-escalation to Interferon-beta-1b in Patients With Relapsing-remitting Multiple Sclerosis

Lugano : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

St. Gallen : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

Zug : Biogen Idec International GmbH, Global Medical Affairs

TOP: IMA-06-02 Tysabri Observational Program

Zurich : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

Syrian Arab Republic

Many Locations :

Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment

Taiwan

Many Locations :

Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment

Tunisia

Mannouba : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Many Locations :

Noninterventional Study Assessing Cognitive Function and Physical Activity in People With Multiple Sclerosis

Monastir : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Sfax : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Tunis : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Turkey

Ankara : Novartis Investigative Site

A 12 -Month, Open-label, Multi-center Study to Explore the Health Outcomes of FTY720

Ankara : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Inciralti Izmir : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Istanbul : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Izmir : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

View More »

Kocaeli : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Samsun : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Trabzon : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Yenisehir-izmir : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Ukraine

Cherkassy : Synthon investigational site 474

Efficacy and Safety of GTR in Comparison to Copaxone®

Chernihiv : Synthon investigational site 459

Efficacy and Safety of GTR in Comparison to Copaxone®

Chernivtsi : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Chernivtsi : Synthon investigational site 463

Efficacy and Safety of GTR in Comparison to Copaxone®

Dnepropetrovsk : Synthon investigational site 458

Efficacy and Safety of GTR in Comparison to Copaxone®

View More »

Dnepropetrovsk : Synthon investigational site 472

Efficacy and Safety of GTR in Comparison to Copaxone®

Dnipropetrovsk : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Dnipropetrovsk : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Donetsk : Synthon investigational site 468

Efficacy and Safety of GTR in Comparison to Copaxone®

Donetsk : Synthon investigational site 464

Efficacy and Safety of GTR in Comparison to Copaxone®

Ivano-Frankivsk : Synthon investigational site 495

Efficacy and Safety of GTR in Comparison to Copaxone®

Kharkiv : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Kharkiv : Synthon investigational site 469

Efficacy and Safety of GTR in Comparison to Copaxone®

Kharkiv : Synthon investigational site 461

Efficacy and Safety of GTR in Comparison to Copaxone®

Kharkov : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Kiev : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Kiev : XX

Phase 3 Study to Evaluate Efficacy and Safety of NU100 in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)

Kyiv : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Kyiv : Synthon investigational site 455

Efficacy and Safety of GTR in Comparison to Copaxone®

Kyiv : Synthon investigational site 496

Efficacy and Safety of GTR in Comparison to Copaxone®

Kyiv : Synthon investigational site 456

Efficacy and Safety of GTR in Comparison to Copaxone®

Lutsk : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Lutsk : Synthon investigational site 473

Efficacy and Safety of GTR in Comparison to Copaxone®

Lviv : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Lviv : Synthon investigational site 462

Efficacy and Safety of GTR in Comparison to Copaxone®

Lviv : Synthon investigational site 466

Efficacy and Safety of GTR in Comparison to Copaxone®

Lviv : Synthon investigational site 497

Efficacy and Safety of GTR in Comparison to Copaxone®

Mariupol : Synthon investigational site 498

Efficacy and Safety of GTR in Comparison to Copaxone®

Odesa : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Odessa : Synthon investigational site 457

Efficacy and Safety of GTR in Comparison to Copaxone®

Poltava : Synthon investigational site 470

Efficacy and Safety of GTR in Comparison to Copaxone®

Simferopol : Synthon investigational site 467

Efficacy and Safety of GTR in Comparison to Copaxone®

Uzhhorod : Synthon investigational site 471

Efficacy and Safety of GTR in Comparison to Copaxone®

Vinnytsia : Synthon investigational site 465

Efficacy and Safety of GTR in Comparison to Copaxone®

Vinnytsya : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Zhytomyr : Synthon investigational site 460

Efficacy and Safety of GTR in Comparison to Copaxone®

United Kingdom

Brighton : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Brighton : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Edgbaston : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Edinburgh : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Exeter : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

View More »

Exeter : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Hammersmith : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Irvine : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Liverpool : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Liverpool : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

London : GSK Investigational Site

[18F]PBR111 and Microglial Activation in Multiple Sclerosis

London : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

London : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

London : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

London : Research Site Updated

Dose-finding Study of MT-1303

London : University College of London, Institute of Neurology

Efficacy of Clean Intermittent Catheterization in MS Patients With Bladder Dysfunction

London : Imperial College NHS Trust

Patient Research Cohort: Rapidly Evolving Multiple Sclerosis

London : Research Site

Safety and Tolerability Study of MEDI-551, a B-cell Depleting Agent, to Treat Relapsing-Remitting Multiple Sclerosis

Manchester : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Manchester : Morhosys Investigative Site

Phase Ib Study to Evaluate MOR103 in Multiple Sclerosis

Many Locations :

Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment

Many Locations :

Study Evaluating Betaferons® Safety and Tolerability In Pediatric Patients With Multiple Sclerosis

Merck KGaA Communication Center for recruiting locations : Please conatact the

The Impact of Disease Modifying Therapies (DMTs) and Associated Support Services on Patient Reported Experience Measures (PREMs) and Outcomes (PROs) in Relapsing Multiple Sclerosis (RMS) Patients

Morriston : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Newcastle Upon Tyne : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Newcastle Upon Tyne : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Norwich : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Nottingham : GSK Investigational Site

[18F]PBR111 and Microglial Activation in Multiple Sclerosis

Nottingham : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Nottingham : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Nottingham : MorphoSys Investigative Site

Phase Ib Study to Evaluate MOR103 in Multiple Sclerosis

Plymouth : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Plymouth : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Sheffield : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Sheffield : Synthon investigational site 284

Efficacy and Safety of GTR in Comparison to Copaxone®

Stoke on Trent : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Stoke on Trent : Synthon investigational site 281

Efficacy and Safety of GTR in Comparison to Copaxone®

Swansea : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Swansea : Research Site

Exploratory Study to Assess the Effect of Fampridine on Walking Ability and Balance in Patients With Multiple Sclerosis.

Torquay : Synthon investigational site 283

Efficacy and Safety of GTR in Comparison to Copaxone®

Truro : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Truro : Synthon investigational site 280

Efficacy and Safety of GTR in Comparison to Copaxone®

Uruguay

Indianapolis : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Venezuela

Many Locations :

Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment